



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Meeting Housekeeping Care and Treatment Committee

Created by Behavioral Science Research

Disclaimer & Code of Conduct

- ❑ Audio of this meeting is being recorded and will become part of the public record.
- ❑ Members serve the interest of the Miami-Dade HIV community as a whole, not private or personal interests
- ❑ Member shall treat all persons, issues, and business fairly.
- ❑ Members shall refrain from side-bar conversations in accordance with Florida Government in the Sunshine laws.

Meeting Participation

Everyone has a role to play!

- ❑ Only Care and Treatment members vote at today's meeting.
- ❑ All attendees may address the board as time allows and at the discretion of the Chair.
- ❑ Please *share your expertise* on the current Agenda topics and motions. Remember to . . .
 - Raise your hand to be recognized by the Chair or added to the queue during discussions.
 - Avoid repeating points previously addressed.
- ❑ Announcements can be made at the end of the meeting as time allows. Announcements should inform or educate the community and must not be used to advance personal interests or any form of financial gain.

About the Partnership

- ❑ The Miami-Dade HIV/AIDS Partnership is the official Ryan White Program Planning Council for Miami-Dade County.
- ❑ Partnership Members are appointed by the Mayor of Miami-Dade County based on recommendations by the Community Coalition Roundtable.
- ❑ The Care and Treatment Committee is one of six Standing Committees of the Partnership.
- ❑ All Partnership and Standing Committee members are volunteers and commit to abiding by the Partnership's Bylaws, including regular meeting attendance and completion of required training and paperwork.
- ❑ See staff after the meeting for additional details.



Language Matters!

Words can be stigmatizing or empowering.

Please consider how we refer to people:
People with HIV, *People* with substance use disorders, *People* who are unhoused, etc.

Please **do not** use these terms when referring to people:
Dirty. Clean. Full-blown AIDS. Victim.

Please don't say, **INFECTED with HIV.**
Instead, say **ACQUIRED HIV, DIAGNOSED with HIV,**
or **CONTRACTED HIV.**

Please don't say **RISKS.** Instead, say **REASONS.**

Resources

- ❑ Behavioral Science Research Corp. (BSR) staff are the Resource Persons for this meeting.
- ❑ See staff after the meeting if you are interested in membership or if you have a question that wasn't covered during the meeting.
- ❑ Find today's presentation and supporting documents at www.partnershipmiami.org or by scanning the QR code on your agenda.

Care and Treatment Committee
Next Meeting: July 9, 2026, at 10:00 a.m.

Care Resource Community Health Centers, 3510 Biscayne Boulevard, 1st Floor Community Room, Miami, FL 33137

AGENDA
July 9, 2026

MINUTES
June 11, 2026

PARTNERSHIP REPORT
Partnership Report of Approved Motions, June 1, 2026

BYLAWS
Click here.

Membership

RETURN TO MENU

Meeting Documents

- 2026 Annual Needs Assessment
 - Planning Council Responsibilities and Needs Assessment
 - Process for Setting Priorities and Allocating Resources
 - MDC Epidemiological Data - Summary
 - RWP HIV Care Continuum
- Other Meeting Documents
 - Medical Care Subcommittee Report, June 2026
 - 2026 Calendar of Activities
- Join the Care and Treatment Committee!
 - Committee Application
 - Mentoring Opportunity

Next Care & Treatment Meeting
Coming Up In ...

007: 20 : 57 : 18

Day Hrs Min Sec

RSVP

Miami-Dade County
2027-2031
Integrated HIV
Prevention and Care Plan

Getting to the Meeting

Reference



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Floor Open to the Public

“Pursuant to Florida Sunshine Law, I want to provide the public with a reasonable opportunity to be heard on any item on our agenda today. If there is anyone who wishes to be heard, I invite you to speak now. Each person will be given three minutes to speak. Please begin by stating your name and address for the record before you talk about your concerns.

“BSR has a dedicated line for statements to be read into the record. No statements were received.”



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



**Care and Treatment Committee Meeting
Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd., 1st Floor, Community Room
Miami, FL 33137**

June 11, 2026, Minutes

#	Committee Members	Present	Absent	Guests
1	Fils Aime, Louvens	X		Dale, Jackie
2	Gonzalez, Yvette	X		Gonzalez de Obando, Tivisay
3	Henriquez, Maria	X		Santiago, Grechen
4	Ingram, Trillion		X	Singh, Hardeep
5	Riley, James	X		
6	Santiago, Steven		X	
7	Shmuels, Daniel	X		
8	Shmuels, Diego		X	
Quorum: 4				Staff
				Gattorno, Frank
				Meizoso, Marlen

All documents referenced in these minutes were accessible to members and the public prior to and during the meeting, at <https://partnershipmiami.org/partnership/#caretreatment2>.

I. Call to Order

Dr. Daniel Shmuels

In the absence of both officers, Dr. Daniel Shmuels volunteered to chair the meeting. He welcomed everyone, reviewed the tasks of the day, and called the meeting to order at 10:20 a.m.

II. Introductions

All

Members, guests, and staff introduced themselves.

III. Meeting Housekeeping

Dr. Daniel Shmuels

Dr. Shmuels reviewed the housekeeping presentation which detailed meeting participation reminders, use of people first language, meeting etiquette, and reminders of access to the meeting materials via the QR code on the agenda.

IV. Floor Open to the Public

Dr. Daniel Shmuels

Dr. Shmuels read the following:

Pursuant to Florida Sunshine Law, I want to provide the public with a reasonable opportunity to be heard on any items on our agenda today. If there is anyone who wishes to be heard, I invite you to speak now. Each person will be given three minutes to speak. Please begin by stating your name and address for the record before you talk about your concerns. BSR has a dedicated line for statements to be read into the record. No statements were received.

There were no comments, so the floor was closed.

V. Review/Approve Agenda

All

The Committee reviewed the agenda. Two additions were requested. For all items marked TBD, Daniel Shmuels should be indicated as the lead. There was also a request for the addition of the Partnership Report after the Medical Care Subcommittee Report. The Committee approved the agenda with the updates and additions.

Motion to accept the agenda with the discussed changes.

Moved: James Riley

Seconded: Yvette Gonzalez

Motion: Passed

VI. Review/Approve Minutes of May 14, 2026

The Committee reviewed the minutes of May 14, 2026, and accepted them as presented.

Motion to accept the May 14, 2026, minutes as presented.

Moved: Louvens Fils Aime

Seconded: Maria Henriquez

Motion: Passed

VII. Reports

Part A

Tivisay Gonzalez de Obando

Tivisay Gonzalez de Obando reviewed the final FY 2025 Ryan White Program Part A/MAI utilization and expenditure reports. The Ryan White Program served 9,316 clients which is slightly fewer clients than last year, though there was an increase in the number of MAI clients served. The carryover request and end of year reports were submitted to HRSA.

Contracts for the current year for EHE, Part A, and MAI are being finalized and will start to go out within the next two weeks.

The public outreach campaign continues.

Recipient staff is preparing for the Ryan White Conference scheduled for August 3-7, 2026.

A member asked if an analysis of carryover has been carried out to show where underspending is taking place. Ms. Gonzalez de Obando indicated the information is available and can be shared with the Committee for the next meeting.

▪ **Other Reports**

There were no Part B, ADAP, or General Revenue reports available for the meeting.

▪ **Vacancies**

Marlen Meizoso

Mrs. Meizoso reviewed the vacancies on the Partnership and the Committee. The two applicants referenced last month were able to attend the meeting and introduced themselves. Jacqueline “Jackie” Dale, and Grechen Santiago provided information on their interest and background. Members decided to vote on their membership as a slate.

Motion to recommend Jackie Dale and Grechen Santiago as members of the Care and Treatment Committee.

Moved: James Riley

Seconded: Yvette Gonzalez

Motion: Passed

Staff reviewed next steps for the new members and also invited committee members to share membership opportunities widely.

▪ **Medical Care Subcommittee Report**

Dr. Daniel Shmuels

Dr. Shmuels read the report from the Medical Care Subcommittee (MCSC). The Medical Care Subcommittee:

- ☐ Heard updates on the Ryan White Program.
- ☐ Continued its review of documents crafted as a response to the HRSA “Dear Colleague” letter reviewing the Allowable Conditions list.
- ☐ Reviewed data on vaccine utilization under Outpatient/Ambulatory Health Services and discussed payor of last resort restrictions for ADAP clients.
- ☐ Discussed special projects and decided to continue current work on allowable conditions.
- ☐ Were informed that dental code D6095-repair of implant abutment, was discontinued, and has not been used recently.
- ☐ Cancelled their June meeting, since several members were not going to be able to attend.

The next MCSC meeting is scheduled for July 24, 2026, at Behavioral Science Research Corp., 2121 Ponce de Leon Boulevard, Suite 240, Coral Gables, FL 33134.

- **Partnership Report**

Marlen Meizoso

Mrs. Meizoso reviewed the Partnership Report which was posted online and indicated the motions made at the June meeting.

VIII. Standing Business

- **FCPN Nomination Care and Treatment Update**

All

The Care and Treatment Committee discussed the need to recommend an additional member to the Florida Comprehensive Planning Network (FCPN) Care and Treatment Division. FCPN works as the state's planning group for HIV services and meets periodically in person and holds workgroups online. Staff forwarded the Bylaws to members which detailed the rules that govern the FCPN. Members were queried for interest in serving as the member and Yvette Gonzalez volunteered. With no additional interest, Ms. Gonzalez was recommended.

Motion to recommend Yvette Gonzalez as the Care and Treatment member to FCPN.

Moved: James Riley

Seconded: Louvens Fils Aime

Motion: Passed

- **Proposed Service Description Protocol**

All

Based on the discussions and review of the proposed Annual Service Description Protocol last month, edits were made and incorporated into the current draft. The protocol is intended to improve the service definition review and approval process. The Committee reviewed the edits which included a sample tracking sheet and language updates. No additional changes were recommended. The Committee made a motion to approve the document as presented.

Motion to accept the Proposed: Annual Service Description Review Protocol as presented.

Moved: Maria Henriquez

Seconded: James Riley

Motion: Passed

IX. New Business

- **Planning Council Responsibilities and Needs Assessment**

All

Mrs. Meizoso reviewed the Planning Council Responsibilities and Needs Assessment presentation which serves as the foundation for the work that the Committee will engage in starting with today's meeting and ending in September. The Committee reviewed their responsibilities, timelines, expectations, and sample data that will be used throughout the process for priority setting, resource allocations, and in establishing directives, emphasizing that decisions must be data driven.

▪ **Needs Assessment PSRA Process Review and Approval**

All

The Committee reviewed the document and took turns reading it out loud. The 2026 Needs Assessment Process for Setting Priorities and Allocating Resources document detailed the step-by-step process members will follow as part of the Annual Needs Assessment which culminates in priority setting and resource allocations (PSRA) of the grant ceiling budgets for the next fiscal year. The Committee made a motion to adopt the document as presented.

Motion to accept the 2026 Needs Assessment Process for Setting Priorities and Allocating Resources document.

Moved: James Riley

Seconded: Louvens Fils Aime

Motion: Passed

▪ **Miami-Dade County Epidemiological Data Selections 2020-2024**

Marlen Meizoso

Mrs. Meizoso reviewed the Miami-Dade County Epidemiological Data Selections from 2020-2024 presentation based on Florida Department of Health data. The presentation highlighted HIV and AIDS incidence by sex, age, ethnic groups, and transmission categories, and HIV prevalence by sex, age, ethnic groups, and transmission categories; compared data to state totals; and highlighted HIV-related deaths, and the HIV Care Continuum.

▪ **Miami-Dade County Ryan White Program Care Continuum FY 2025-26**

Frank Gattorno

Mr. Gattorno reviewed the 2025 Ryan White HIV Care Continuum. HIV Care Continuum client health outcomes continued to improve from FY 2024 to FY 2025. Retained in care rates rose from 80% to 82%, and viral suppression rates rose from 86% to 88%. Among race/ethnicity groups, Black/non-Hispanic have the lowest suppressed viral load rates (83%) while Hispanics have the highest (90%). By sex, men have slightly higher viral suppression rates (89%), compared to women (86%). Among exposure categories, rates for injection drug use (IDU) have the lowest viral suppression rates (78%).

X. Announcements and Open Discussion

All

Attendees were reminded:

- The next New Member Orientation training will be on July 1, 2026, and registration for the event is accessible via the posted QR code or link.
- It is important to RSVP to the meeting for quorum and to prepare sufficient meeting materials during the Needs Assessment meetings. Rapid reallocation will be on the agenda for the July meeting.
- To complete the online evaluation of today's meeting using the projected QR code, staff will also send it via email. The evaluations assist with future planning.

There were no open discussion items.

XI. Next Meeting

Dr. Daniel Shmuels

The next meeting is scheduled for Thursday, July 9, 2026, at Care Resource, from 10:00 a.m. to 1:00 p.m.

XII. Adjournment

Dr. Daniel Shmuels

With business concluded, Dr. Shmuels thanked everyone for participating, and adjourned the meeting at 12:09 p.m.



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

MONTHLY AND YEAR-TO-DATE SERVICE UTILIZATION SUMMARY

FOR THE PERIOD OF:

May 2026

FUNDING SOURCE(S) INCLUDED:

Ryan White Part A
Ryan White MAI

SERVICE CATEGORIES

Core Medical Services

AIDS Pharmaceutical Assistance (LPAP/CPAP)
Health Insurance Premium and Cost Sharing Assistance
Medical Case Management
Mental Health Services
Oral Health Care
Outpatient Ambulatory Health Services
Substance Abuse Outpatient Care

Support Services

Food Bank/Home Delivered Meals
Medical Transportation
Other Professional Services
Outreach Services
Substance Abuse Services (residential)

Service Units		Unduplicated Client Count	
Monthly	Year-to-date	Monthly	Year-to-date
5	18	3	5
0	28	0	12
7,617	28,673	4,066	6,680
20	213	13	80
938	2,964	683	1,422
2,695	9,125	1,671	3,571
2	5	1	2
830	2,445	303	405
115	928	111	386
0	0	0	1
98	229	35	72
543	1,468	26	32
TOTALS:			

Total unduplicated clients (month):

5,032

Total unduplicated clients (YTD):

7,496

See page 4 for
Service Unit
Definitions

MONTHLY AND YEAR-TO-DATE SERVICE UTILIZATION SUMMARY

FOR THE PERIOD OF:

May 2026

FUNDING SOURCE(S) INCLUDED:

Ryan White Part A

SERVICE CATEGORIES

	Service Units		Unduplicated Client Count	
	Monthly	Year-to-date	Monthly	Year-to-date
Core Medical Services				
AIDS Pharmaceutical Assistance (LPAP/CPAP)	5	18	3	5
Health Insurance Premium and Cost Sharing Assistance	0	28	0	12
Medical Case Management	6,709	23,311	3,734	5,869
Mental Health Services	6	174	2	57
Oral Health Care	938	2,964	683	1,422
Outpatient Ambulatory Health Services	2,551	8,583	1,607	3,442
Substance Abuse Outpatient Care	2	5	1	2
Support Services				
Food Bank/Home Delivered Meals	830	2,445	303	405
Medical Transportation	92	831	90	349
Other Professional Services	0	0	0	1
Outreach Services	97	219	34	63
Substance Abuse Services (residential)	543	1,468	26	32
TOTALS:	11,773	40,046		
Total unduplicated clients (month):	4,828			
Total unduplicated clients (YTD):	7,103			

MONTHLY AND YEAR-TO-DATE SERVICE UTILIZATION SUMMARY

FOR THE PERIOD OF:

May 2026

FUNDING SOURCE(S) INCLUDED:

Ryan White MAI

SERVICE CATEGORIES

Core Medical Services

Medical Case Management

Mental Health Services

Outpatient Ambulatory Health Services

Support Services

Medical Transportation

Outreach Services

	Service Units		Unduplicated Client Count	
	Monthly	Year-to-date	Monthly	Year-to-date
Medical Case Management	908	5,362	458	1,526
Mental Health Services	14	39	11	23
Outpatient Ambulatory Health Services	144	542	125	332
Medical Transportation	23	97	21	48
Outreach Services	1	10	1	9
TOTALS:	1,090	6,050		
Total unduplicated clients (month):	535			
Total unduplicated clients (YTD):	1,638			

Miami-Dade County Ryan White Part A/MAI Program

Service Unit Definitions

Service Categories	Service Unit Definition
Core Medical Services	
AIDS Pharmaceutical Assistance (Local Pharmaceutical Assistance Program; LPAP)	1 filled prescription
Health Insurance Premium & Cost Sharing Assistance	1 health insurance payment (copayment or deductible)
Medical Case Management (MCM; Incl. Treatment Adherence)	1 MCM encounter
Mental Health Services	1 individual or group encounter
Oral Health Care	1 oral health care visit
Outpatient/Ambulatory Health Services	1 medical visit
Substance Abuse Outpatient Care	1 individual or group encounter
Support Services	
Emergency Financial Assistance (limited access)	1 filled prescription
Food Bank	1 bag of groceries
Medical Transportation	1 medical transportation voucher or one-way rideshare trip
Other Professional Services (Legal Assistance & Permanency Planning)	1 hour of legal assistance
Outreach Services	1 individual encounter
Substance Abuse Services-Residential	1 day of residential substance abuse services

NOTE: MAI-funded services are limited to minority clients from priority subpopulations or emerging need subpopulations.



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

FL ADAP Formulary Update

Good afternoon [Florida ADAP Resources](#),

We are writing to provide an important update regarding recent changes to the Florida AIDS Drug Assistance Program (ADAP) formulary. As communicated to our partners, the updated formulary- reflecting the addition of Biktarvy back onto the ADAP formulary and the removal of the Prior Authorization requirement for Descovy- has now been fully implemented starting July 1st, 2026. I have attached the new formulary for your reference.

Prime Therapeutics has confirmed that their Benefit Configuration team has lifted the previous edits associated with both products. Additionally, their Provider Relations team has initiated a network-wide fax and email notification to ensure all pharmacies are aware of the changes. The **ADAP portal will reflect the updated formulary effective July 1, 2026.**

We understand that pharmacies may have questions regarding the temporary period (March 1–June 30) during which Biktarvy was removed from the formulary. We will issue further guidance shortly to support consistent and accurate messaging should pharmacy staff or clients request clarification.

We appreciate the collaboration across teams to ensure continuity of care for our uninsured and insured ADAP client communities and timely communication across the provider network.

Please feel free to reach out with any additional questions or if further clarification is needed.

Thank you



ADAP Formulary July 2026....



Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Brand Name (listed for Antiretroviral drugs only)	Therapeutic Classification	Pharmacologic Classification
abacavir	Ziagen	Antiretroviral	NRTI
abacavir / lamivudine	Epzicom	Antiretroviral	NRTI combo
abacavir / dolutegravir / lamivudine	Triumeq	Antiretroviral	INSTI/NRTI combo
atazanavir	Reyataz	Antiretroviral	PI
atazanavir/cobicistat	Evotaz	Antiretroviral	PI/PK Enhancer
bictegravir / emtricitabine / tenofovir alafenamide	Biktarvy	Antiretroviral	INSTI/NRTI combo
cabotegravir	Vocabria	Antiretroviral	INSTI
cabotegravir / rilpivirine	Cabenuva	Antiretroviral	INSTI/NNRTI combo
cobicistat	Tybost	Antiretroviral	PK Enhancer
darunavir	Prezista	Antiretroviral	PI
darunavir / cobicistat	Prezcobix	Antiretroviral	PI/PK Enhancer
darunavir / cobicistat / emtricitabine / tenofovir alafenamide	Symtuza	Antiretroviral	PI/NRTI combo
dolutegravir	Tivicay	Antiretroviral	INSTI
dolutegravir / lamivudine	Dovato	Antiretroviral	INSTI/NRTI combo
dolutegravir / rilpivirine	Juluca	Antiretroviral	INSTI/NNRTI combo
doravirine	Pifeltro	Antiretroviral	NNRTI
doravirine / lamivudine / tenofovir disoproxil fumarate	Delstrigo	Antiretroviral	NNRTI/NRTI combo
efavirenz	Sustiva	Antiretroviral	NNRTI
efavirenz / emtricitabine / tenofovir disoproxil fumarate	N/A	Antiretroviral	NNRTI/NRTI combo
efavirenz / lamivudine / tenofovir disoproxil fumarate	Symfi, SymfiLo	Antiretroviral	NNRTI/NRTI combo
elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide	Genvoya	Antiretroviral	INSTI/NRTI combo
elvitegravir / cobicistat / emtricitabine /tenofovir disoproxil fumarate	Stribild	Antiretroviral	INSTI/NRTI combo
emtricitabine	Emtriva	Antiretroviral	NRTI
emtricitabine / tenofovir alafenamide	Descovy	Antiretroviral	NRTI combo
emtricitabine / tenofovir disoproxil fumarate	Truvada	Antiretroviral	NRTI combo
enfuvirtide	Fuzeon	Antiretroviral	Fusion inhibitor
etravirine	Intelence	Antiretroviral	NNRTI
fostemsavir	Rukobia	Antiretroviral	Gp-120 directed attachment inhibitor
ibalizumab-uiyk injection ^{PA}	Trogarzo ^{PA}	Antiretroviral	CD4 post-attachment HIV-1 inhibitor
lamivudine	Epivir	Antiretroviral	NRTI
lamivudine / zidovudine	Combivir	Antiretroviral	NRTI combo
lenacapavir	Sunlenca	Antiretroviral	Capsid inhibitor
lopinavir / ritonavir	Kaletra	Antiretroviral	PI/PK Enhancer
maraviroc	Selzentry	Antiretroviral	CCR5 antagonist
nevirapine, nevirapine XR	Viramune, Viramune XR	Antiretroviral	NNRTI
raltegravir, raltegravir HD	Isentress, Isentress HD	Antiretroviral	INSTI
rilpivirine	Edurant	Antiretroviral	NNRTI
rilpivirine / emtricitabine/ tenofovir disoproxil fumarate	Complera	Antiretroviral	NNRTI/NRTI combo
rilpivirine / emtricitabine / tenofovir alafenamide	Odefsey	Antiretroviral	NNRTI/NRTI combo
ritonavir	Norvir	Antiretroviral	PK Enhancer
tenofovir alafenamide	Vemlidy	Antiretroviral	NRTI
tenofovir disoproxil fumarate	Viread	Antiretroviral	NRTI

tenofovir disoproxil fumarate / lamivudine	Cimduo, Temixys	Antiretroviral	NRTI combo
zidovudine	Retrovir	Antiretroviral	NRTI
Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026 ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
acetaminophen	Analgesic	Non-salicylate analgesic	capsule, tablet, oral liquid, rectal suppository
acetaminophen/hydrocodone ^{CS}	Analgesic	Nonsalicylate/opioid	capsule, tablet, oral liquid
acetaminophen/oxycodone ^{CS}	Analgesic	Nonsalicylate/opioid	tablet, oral liquid
acetazolamide	Antiglaucoma	Carbonic anhydrase inhibitor	capsule, tablet
acyclovir	Anti-infective	Antiviral	capsule, tablet, oral liquid, topical
albuterol	Respiratory	Beta-2 Agonist	inhaler, nebulizer solution, tablet, oral liquid
albuterol HFA	Respiratory	Beta-2 Agonist	inhaler
albuterol/ipratropium	Respiratory	Anticholinergic + Beta-2 Agonist, oral inhaled	inhaler, nebulizer solution
alendronate	Osteoporosis	Bisphosphonate	tablet, oral liquid
alirocumab	Cardiovascular, antihyperlipidemic	PCSK9 inhibitor	injection
allopurinol	Antigout	Xanthine oxidase inhibitor	tablet
amitriptyline	Central nervous system, antidepressant	Tricyclic antidepressant (TCA)	tablet
amlodipine	Cardiovascular	Calcium channel blocker	tablet, oral liquid
amlodipine/atorvastatin	Cardiovascular	Calcium channel blocker/HMG-CoA reductase inhibitor	tablet
amlodipine/benazepril	Cardiovascular	Calcium channel blocker/ACE inhibitor	capsule
amlodipine/olmesartan	Cardiovascular, antihypertensive	Calcium channel blocker/angiotensin II receptor blocker	tablet
amlodipine/valsartan	Cardiovascular, antihypertensive	Calcium channel blocker/angiotensin II receptor blocker	tablet
ammonium lactate	Dermatologic	Humectant	topical
amoxicillin	Anti-infective	Beta-lactam antibiotic	capsule, tablet, oral liquid
amoxicillin/clavulanate	Anti-infective	Beta-lactam antibiotic/beta-lactamase inhibitor	tablet, oral liquid
amphetamine/dextroamphetamine ^{CS}	Central nervous system	ADHD agent, stimulant	tablet, capsule
apixaban	Blood formation and coagulation	Anticoagulant	tablet
aripiprazole	Central nervous system	Antipsychotic, atypical	tablet, injection
aspirin	Analgesic	Salicylate	caplet, tablet, rectal suppository
atenolol	Cardiovascular	Beta-blocker	tablet
atenolol/chlorthalidone	Cardiovascular	Beta-blocker/thiazide-like diuretic	tablet
atomoxetine	Central nervous system	ADHD agent, non-stimulant	capsule
atorvastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet, oral liquid
atovaquone	Anti-infective	Amebicide	oral liquid
azelastine	Respiratory	Antihistamine	nasal spray, eye drops
azelastine/fluticasone	Respiratory	Antihistamine/corticosteroid, intranasal	nasal spray
azithromycin	Anti-infective	Macrolide antibiotic	tablet, oral liquid, eye drops
baclofen	Central nervous system	Muscle relaxant	tablet, oral liquid
baloxavir	Anti-infective	Anti-influenza antiviral	tablet, oral liquid
beclomethasone	Respiratory	Corticosteroid	nasal spray, inhaler
bempedoic acid	Cardiovascular, antihyperlipidemic	ACL inhibitor	tablet
benazepril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet
benazepril/hydrochlorothiazide	Cardiovascular	ACE inhibitor/ thiazide diuretic	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

^{CS} indicates controlled substance. ^{PA} indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
benzoyl peroxide	Dermatologic	Antibiotic + keratolytic	topical
benzoyl peroxide/clindamycin	Dermatologic	Anti-acne retinoid	topical
benztropine	Central nervous system	Anticholinergic	tablet
betamethasone dipropionate	Dermatologic	Corticosteroid	topical
betamethasone valerate	Dermatologic	Corticosteroid	topical
betamethasone/clotrimazole	Dermatologic	Corticosteroid, antifungal	topical
bisacodyl	Gastrointestinal	Laxative, stimulant	tablet, rectal suppository
bismuth subcitrate potassium/metronidazole/tetracycline	Gastrointestinal	Helicobacter pylori agents	tablets and capsules (therapy kit)
brexpiprazole	Central nervous system	Antipsychotic, atypical	tablet
brimonidine	Antiglaucoma	Alpha-2 agonist	eye drops, eye gel
brimonidine/timolol	Antiglaucoma	Alpha agonist/beta blocker	eye drops
budesonide	Respiratory	Corticosteroid	inhaler, nasal spray
budesonide/formoterol	Respiratory	Corticosteroid + Long acting Beta-2 Agonist, oral inhaled	inhaler
budesonide/glycopyrrolate/formoterol	Respiratory	Corticosteroid/anticholinergic/long-acting Beta-2 agonist	inhaler
buprenorphine/naloxone ^{CS}	Substance abuse	Opiate agonist/antagonist	tablet, oral film
buprenorphine ^{CS}	Substance abuse	Opiate agonist/antagonist	tablet, oral film, patch
bupropion	Central nervous system	Antidepressant-miscellaneous, aminoketone	tablet
buspirone	Central nervous system	Anxiolytic	tablet
calcium carbonate	Vitamin	Vitamin	tablet, oral liquid
calcium with vitamin D	Vitamin	Vitamin	tablet
canagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
canagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
capsaicin	Dermatologic	Analgesic	topical
carbamazepine	Central nervous system	Anti-manic, anti-seizure	tablet, capsule
carbamide peroxide	Otic	Ear wax removal agent	ear drops, oral liquid
carboxymethylcellulose	Ophthalmic	Lubricating agent	eye drops
carvedilol	Cardiovascular	Beta-blocker	capsule, tablet
cefdinir	Anti-infective	Cephalosporin antibiotic	capsule, oral liquid
cefixime	Anti-infective	Cephalosporin antibiotic	capsule, tablet, oral liquid
ceftriaxone	Anti-infective	Cephalosporin antibiotic	injection
celecoxib	Analgesic	COX-II Inhibitor Non-steroidal anti-inflammatory drug	capsule, oral liquid
cephalexin	Anti-infective	Cephalosporin antibiotic	capsule, tablet, oral liquid
cetirizine	Respiratory	Antihistamine	tablet, oral liquid
chlorhexidine gluconate (0.12%)	Dermatologic	Anti-infective	oral liquid
chlorthalidone	Cardiovascular	Thiazide-like diuretic	tablet
cholecalciferol (vitamin D3)	Vitamin	Vitamin	capsule, tablet, oral liquid
ciprofloxacin	Anti-infective	Quinolone antibiotic	tablet, ear drops, eye drops, oral liquid
ciprofloxacin/dexamethasone	Anti-infective/anti-inflammatory	Quinolone antibiotic/corticosteroid	ear drops
citalopram	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
clarithromycin	Anti-infective	Macrolide antibiotic	tablet, oral liquid
clindamycin	Anti-infective	Lincosamide antibiotic	capsule, oral liquid, topical
clonazepam ^{CS}	Central nervous system	Benzodiazepine	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****
^{CS} indicates controlled substance. ^{PA} indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
clonidine	Cardiovascular	Centrally acting alpha 2 agonist	tablet, oral liquid, patch
clopidogrel	Cardiovascular	Platelet inhibitor	tablet
clotrimazole	Anti-infective	Azole antifungal	oral troche, topical
conjugated estrogens (topical only)	Dermatologic	Estrogen	topical
crofelemer	Gastrointestinal	Antidiarrheal	tablet
cyanocobalamin (vitamin B12)	Vitamin	Vitamin	tablet, oral liquid, nasal spray, injection
cyclobenzaprine	Central nervous system	Muscle relaxant	capsule, tablet
cyproheptadine	Respiratory	Antihistamine	tablet, oral liquid
dabigatran	Blood formation and coagulation	Anticoagulant	capsule, oral granules
dapagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
dapagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
dapsone	Anti-infective	Sulfone antibiotic	tablet, topical
dexamethasone/neomycin/polymyxin b	Ophthalmic	Corticosteroid/antibacterial	eye drops, eye ointment
dextromethorphan/promethazine	Respiratory	Antitussive/antihistamine	oral liquid
diazepam ^{CS}	Central nervous system	Benzodiazepine	tablet, oral liquid, nasal spray, rectal gel
diclofenac	Analgesic	Non-steroidal anti-inflammatory drug	capsule, tablet, eye drops, topical
dicyclomine	Gastrointestinal	Antispasmodic	capsule, tablet, oral liquid
digoxin	Cardiovascular	Cardiac glycoside	tablet, oral liquid
diltiazem	Cardiovascular	Calcium channel blocker	capsule, tablet
diphenhydramine	Respiratory	Antihistamine	capsule, tablet, oral liquid, topical
diphenoxylate/atropine ^{CS}	Gastrointestinal	Antidiarrheal	tablet, oral liquid
disulfiram	Substance abuse	Alcohol deterrent	tablet
divalproex	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet, oral liquid
docusate sodium	Gastrointestinal	Laxative, stool softener	capsule, tablet, oral liquid
donepezil	Central nervous system	Cholinesterase inhibitor	tablet, patch
dorzolamide	Antiglaucoma	Carbonic anhydrase inhibitor	eye drops
dorzolamide/ timolol	Antiglaucoma	Carbonic anhydrase inhibitor, beta-blocker	eye drops
doxazosin	Cardiovascular	Alpha-blocker	tablet
doxepin	Central nervous system	Tricyclic antidepressant (TCA)	capsule, tablet, oral solution, topical
doxycycline	Anti-infective	Tetracycline antibiotic	capsule, tablet, oral liquid
doxylamine/pyridoxine	Gastrointestinal	Anti-nausea agent	tablet
dronabinol ^{CS}	Gastrointestinal, appetite stimulant	Cannabinoid	capsule, oral liquid
dulaglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	injection
duloxetine	Central nervous system, antidepressant	Serotonin-norepinephrine reuptake inhibitor	capsule
elbasvir/grazoprevir	Anti-infective	Hepatitis C antiviral	tablet
empagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
empagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
enalapril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet, oral liquid
enalapril/hydrochlorothiazide	Cardiovascular	ACE inhibitor/ thiazide diuretic	tablet
entecavir	Anti-infective	Hepatitis B antiviral	tablet, oral liquid
epoetin alfa	Blood formation and coagulation	Erythropoiesis stimulating agent	injection

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
ergocalciferol (vitamin D2)	Vitamin	Vitamin	capsule, tablet, oral liquid
escitalopram	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	tablet, oral liquid
esomeprazole	Gastrointestinal	Proton pump inhibitor	capsule, tablet, oral powder
estradiol	Endocrine	Estrogen	tablet, topical, injection
ethambutol	Anti-infective	Antimycobacterial	tablet
ethinyl estradiol/desogestrel	Endocrine	Estrogen/Progestin	tablet
ethinyl estradiol/etonogestrel	Endocrine	Estrogen/Progestin	vaginal ring
ethinyl estradiol/levonorgestrel	Endocrine	Estrogen/progestin	tablet, patch
ethinyl estradiol/norethindrone	Endocrine	Estrogen/progestin	tablet
ethinyl estradiol/norethindrone/ferrous fumarate	Endocrine	Estrogen/progestin/iron	tablet
ethinyl estradiol/norgestimate	Endocrine	Estrogen/progestin	tablet
ethinyl estradiol/norgestrel	Endocrine	Estrogen/progestin	tablet
evolocumab	Cardiovascular, antihyperlipidemic	PCSK9 inhibitor	injection
ezetimibe	Cardiovascular, antihyperlipidemic	Cholesterol absorption inhibitor	tablet
ezetimibe/rosuvastatin	Cardiovascular, antihyperlipidemic	Cholinesterase inhibitor/HMG CoA reductase inhibitor	tablet
famciclovir	Anti-infective	Antiviral	tablet
famotidine	Gastrointestinal, acid reducing	Histamine 2 receptor blocker	tablet, oral powder
fenofibrate	Cardiovascular, antihyperlipidemic	Fibric acid derivative	capsule, tablet
ferrous sulfate	Vitamin	Vitamin	tablet, oral liquid
fexofenadine	Respiratory	Antihistamine	tablet, oral liquid
fidaxomicin	Anti-infective	Macrolide antibiotic	tablet, oral powder
filgrastim	Blood formation and coagulation	Granulocyte stimulating agent	injection
finasteride	Genitourinary	5-Alpha Reductase Inhibitor	tablet
fluconazole	Anti-infective	Azole antifungal	tablet, oral liquid
flunisolide (nasal spray)	Respiratory	Corticosteroid, nasal	nasal spray
fluoxetine	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
fluoxetine/olanzapine	Central nervous system	SSRI/atypical antipsychotic, antimanic	capsule
fluticasone	Respiratory	Corticosteroid	inhaler, nasal spray
fluticasone furoate/umeclidinium/vilanterol	Respiratory	Corticosteroid/long-acting muscarinic antagonist/long-acting Beta-2 agonist	inhaler
fluticasone/salmeterol	Respiratory	Corticosteroid + Long acting Beta-2 Agonist, oral inhaled	inhaler
fluticasone/vilanterol	Respiratory	Corticosteroid/long-acting Beta-2 agonist	inhaler
folic acid	Vitamin	Vitamin	capsule, tablet
formoterol	Respiratory	Long-acting Beta-2 agonist	inhaler, nebulizer solution
frovatriptan	Central nervous system	Antimigraine	tablet
furosemide	Cardiovascular	Loop diuretic	tablet, oral liquid
gabapentin	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet
gemfibrozil	Cardiovascular, antihyperlipidemic	Fibric acid derivative	tablet
glecaprevir/pibrentasvir	Anti-infective	Hepatitis C antiviral	tablet, oral pellet packet
glimepiride	Antidiabetic	Sulfonylurea	tablet
glipizide	Antidiabetic	Sulfonylurea	tablet
glipizide/metformin	Antidiabetic	Sulfonylurea/biguanide	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
glyburide	Antidiabetic	Sulfonylurea	tablet
glyburide/metformin	Antidiabetic	Sulfonylureas/Biguanides	tablet
glycopyrrolate	Respiratory	Anticholinergic	tablet, oral liquid
hepatitis A adult vaccine	Vaccines	Viral vaccine	injection
hepatitis A/B vaccine	Vaccines	Viral vaccine	injection
hepatitis B adult vaccine	Vaccines	Viral vaccine	injection
hepatitis B vaccine (recombinant, adjuvanted)	Vaccines	Viral vaccine	injection
human papilloma virus vaccine (recombinant)	Vaccines	Viral vaccine	injection
hydralazine	Cardiovascular	Vasodilating agents	tablet
hydrochlorothiazide	Cardiovascular	Thiazide diuretic	capsule, tablet
hydrocortisone	Anti-inflammatory	Corticosteroid	topical, tablet, enema
hydrocortisone/neomycin/polymyxin b	Anti-inflammatory/anti-infective	Corticosteroid/antibacterial	ear drops
hydrocortisone/pramoxine	Anti-inflammatory/anesthetic	Corticosteroid/anesthetic	topical
hydroxyzine	Respiratory or CNS	Antihistamine or anxiolytic	capsule, tablet, oral liquid
hyoscyamine	Gastrointestinal	Antispasmodic	tablet oral liquid
ibuprofen	Analgesic	Nonsteroidal anti-inflammatory drug	capsule, tablet, oral liquid
imiquimod	Dermatologic	Immune response modifier	topical
influenza vaccine (including high dose)	Vaccines	Viral vaccine	injection
inhaler spacer (one time only)	Respiratory	Inhaler spacer device	spacer device
insulin aspart	Antidiabetic	Insulin-rapid acting	injection
insulin degludec	Antidiabetic	Insulin	injection
insulin detemir	Antidiabetic	Insulin intermediate to long acting	injection
insulin glargine	Antidiabetic	Insulin-long acting	injection
insulin isophane (NPH)	Antidiabetic	Insulin-intermediate acting	injection
insulin lispro	Antidiabetic	Insulin-rapid acting	injection
insulin NPH and insulin regular	Antidiabetic	Insulin-70/30	injection
insulin regular	Antidiabetic	Insulin-short acting	injection
ipratropium	Respiratory	Anticholinergic	inhaler, nebulizer solution
irbesartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet
irbesartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
isoniazid	Anti-infective	Antimycobacterial	tablet, oral liquid
isosorbide dinitrate	Cardiovascular	Vasodilating agents	tablet
isosorbide mononitrate	Cardiovascular	Vasodilating agents	tablet
itraconazole	Anti-infective	Azole antifungal	capsule, oral liquid
ivabradine	Cardiovascular	Hyperpolarization-activated cyclic nucleotide-gated channel blocker	tablet, oral liquid
ketoconazole	Anti-infective	Azole antifungal	tablet, topical
labetalol	Cardiovascular	Beta-blocker	tablet
lactulose	Gastrointestinal	Laxative, osmotic	oral liquid
lamotrigine	Central nervous system	Anticonvulsant, mood stabilizer	tablet, oral liquid
lanolin alcohol-mo-w.pet-ceres (Eucerin)	Emollient	Moisturizer	topical
lansoprazole	Gastrointestinal	Proton pump inhibitor	capsule, tablet
lanthanum carbonate	Gastrointestinal	Phosphate binder	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
latanoprost	Antiglaucoma	Prostaglandin	eye drops
ledipasvir/sofosbuvir	Anti-infective	Hepatitis C antiviral	tablets, oral pellet packet
leucovorin	Vitamin	Vitamin	tablet
levetiracetam	Central nervous system	Anticonvulsant, mood stabilizer	tablet, oral liquid
levofloxacin	Anti-infective	Quinolone antibiotic	tablet, oral liquid
levonorgestrel	Endocrine	Progestin	tablet, intrauterine device
levothyroxine	Endocrine	Thyroid supplement	tablet
lidocaine	Anesthetic	Anesthetic	topical
linaclotide	Gastrointestinal	Irritable bowel syndrome agent	capsule
liothyronine	Endocrine	Thyroid supplement	tablet
liraglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	injection
lisinopril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet
lisinopril/hydrochlorothiazide	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor/ thiazide	tablet
lithium carbonate	Central nervous system	Mood stabilizer	capsule, tablet
loperamide	Gastrointestinal, antidiarrheal	Antidiarrheal	capsule, tablet, oral liquid
loratadine	Respiratory	Antihistamine	capsule, tablet, oral liquid
lorazepam ^{CS}	Central nervous system	Benzodiazepine	tablet, oral liquid
losartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet
losartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
loteprednol etabonate	Ophthalmic	Corticosteroid	eye drops, eye gel
lurasidone	Central nervous system	Antipsychotic, atypical	tablet
magnesium oxide	Vitamin	Vitamin	capsule tablet
measles, mumps, rubella vaccine	Vaccines	Viral vaccine	injection
meclizine	Central nervous system	Antivertigo, antiemetic	tablet
medroxyprogesterone	Endocrine	Progestin	tablet, injection
megestrol	Gastrointestinal, appetite stimulant	Endocrine, progestin	tablet, oral liquid
meloxicam	Analgesic	Non-steroidal anti-inflammatory drug	capsule, tablet
meningococcal conjugate vaccine	Vaccines	Bacterial vaccine	injection
mesalamine	Gastrointestinal	5-Aminosalicylate	capsule, tablet, enema, rectal suppository
metformin	Antidiabetic	Biguanide	tablet
metformin/sitagliptin	Antidiabetic	Biguanide/DPP-4 inhibitor	tablet
methylcellulose	Gastrointestinal	Laxative, bulk-forming	oral powder, tablet
methylprednisolone	Endocrine	Glucocorticoid	tablet
metoclopramide	Gastrointestinal	Antiemetic, prokinetic	tablet, oral liquid, nasal spray
metoprolol succinate	Cardiovascular	Beta-blocker	capsule, tablet
metoprolol tartrate	Cardiovascular	Beta-blocker	tablet
metoprolol tartrate/hydrochlorothiazide	Cardiovascular	Beta-blocker/thiazide diuretic	tablet
metronidazole	Anti-infective	Amebicide, trichomonaside	capsule, tablet, topical
midodrine	Cardiovascular	Vasopressor	tablet
mirtazapine	Central nervous system	Tetracyclic antidepressant	tablet
modafinil	Central nervous system	Stimulant	tablet
mometasone	Respiratory or Dermatologic	Corticosteroid	inhaler, nasal spray, topical

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
mometasone/formoterol	Respiratory	Corticosteroid/long-acting Beta-2 agonist	inhaler
mometasone/olopatadine	Respiratory	Corticosteroid/antihistamine	nasal spray
montelukast	Respiratory	Leukotriene receptor antagonist	tablet, oral granules
moxifloxacin	Anti-infective	Quinolone antibiotic	tablet, eye drops
multivitamin	Vitamin	Vitamin	tablet
multivitamin prenatal	Vitamin	Vitamin	tablet
multivitamin with minerals	Vitamin	Vitamin	tablet
mupirocin	Dermatologic	Antibiotic	topical
naloxone	Substance abuse	Opiate antagonist	nasal spray, injection
naltrexone	Substance abuse	Opiate antagonist	capsule, tablet, injection
naltrexone ER/bupropion ER	Anti-obesity	Anorectic agents	tablet
naproxen	Analgesic	Nonsteroidal anti-inflammatory drug	tablet, oral liquid
naratriptan	Central nervous system	Antimigraine	tablet
nepafenac	Anti-inflammatory	Non-steroidal anti-inflammatory drug	eye drops
niacin	Cardiovascular, antihyperlipidemic	Vitamin, lipotropic	capsule, tablet
nicotine	Substance abuse	Nicotine replacement	gum, inhaler, lozenge, nasal spray, patch
nifedipine	Cardiovascular	Calcium channel blocker	capsule, tablet
nitrofurantoin	Anti-infective	Nitrofuans derivative	capsule, oral liquid
nitroglycerin	Cardiovascular	Vasodilating agents	capsule, nasal spray, tablet, topical
norethindrone	Endocrine	Progestin	tablet
nortriptyline	Central nervous system, antidepressant	Tricyclic antidepressant (TCA)	capsule, oral liquid
nystatin	Anti-infective	Antifungal	tablet, oral liquid, topical
olanzapine	Central nervous system	Antipsychotic, antimanic	tablet, injection
olmesartan	Cardiovascular	Angiotensin II receptor blocker	tablet
olmesartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
olopatadine	Respiratory	Anti-histamine	eye drops, nasal spray
omega 3 (icosapent ethyl)	Cardiovascular, antihyperlipidemic	Lipotropic	capsule
omega-3-acid ethyl esters	Cardiovascular, antihyperlipidemic	Lipotropic	capsule
omeprazole	Gastrointestinal, acid reducing	Proton pump inhibitor	capsule, tablet, oral liquid
ondansetron	Central nervous system	Anti-nausea	tablet, oral film
orlistat	Anti-obesity	Gastrointestinal lipase inhibitor	capsule
oseltamivir	Anti-infective	Anti-influenza antiviral	capsule, oral liquid
oxybutynin	Genitourinary	Bladder antispasmodic	tablet, oral liquid, topical
oxycodone ^{CS}	Analgesic	Opiate	capsule, tablet, oral liquid
pancrelipase (amylase, lipase, protease)	Gastrointestinal	Pancreatic enzyme replacement	capsule, tablet
pantoprazole	Gastrointestinal, acid reducing	Proton pump inhibitor	tablet, oral granules, oral liquid
paromomycin	Anti-infective	Amebicide	capsule
paroxetine	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
penicillin	Anti-infective	Beta-lactam antibiotic	tablet, oral liquid, injection
permethrin	Dermatologic	Anti-infective, scabicide	topical
pioglitazone	Antidiabetic	Thiazolidinedione (glitazone)	tablet
pitavastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

^{CS} indicates controlled substance. ^{PA} indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
pneumococcal 15-valent conjugate vaccine	Vaccines	Bacterial vaccine	injection
pneumococcal 20-valent conjugate vaccine	Vaccines	Bacterial vaccine	injection
pneumococcal 23-polyvalent vaccine	Vaccines	Bacterial vaccine	injection
podofilox	Dermatologic	Antiviral	topical
polycarbophil	Gastrointestinal	Laxative, bulk-forming	tablet
polyethylene glycol and electrolytes	Gastrointestinal	Osmotic laxative	oral liquid
polyethylene glycol/propylene glycol	Ophthalmic	Lubricating agent	eye drops
polysaccharide-iron complex	Vitamin	Vitamin	capsule
potassium chloride	Cardiovascular	Electrolyte replacement	capsule, tablet, oral liquid
prasugrel	Cardiovascular	Platelet inhibitor	tablet
pravastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet
prazosin	Cardiovascular	Anti-hypertensive, Alpha-blocker	capsule
prednisolone	Endocrine	Corticosteroid	tablet, oral liquid, eye drops
prednisone	Endocrine	Corticosteroid	tablet, oral liquid
pregabalin ^{CS}	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet, oral liquid
primaquine	Anti-infective	Antimalarial	tablet
promethazine	Gastrointestinal	Antihistamine, antiemetic	tablet, oral liquid, rectal suppository
propranolol	Cardiovascular	Beta-blocker	tablet, capsule, oral liquid
psyllium	Gastrointestinal	Laxative, bulk-forming	capsule, oral powder
pyrazinamide	Anti-infective	Antimycobacterial	tablet
pyridoxine (vitamin B6)	Vitamin	Vitamin	capsule, tablet, oral liquid
pyrimethamine	Anti-infective	Antimalarial	tablet
quetiapine	Central nervous system	Antipsychotic, antimanic	tablet
respiratory syncytial virus (RSV) vaccine	Vaccines	Viral vaccine	injection
respiratory syncytial virus (RSV) vaccine, adjuvanted	Vaccines	Viral vaccine	injection
ribavirin	Anti-infective	Hepatitis C antiviral	capsule, tablet
rifabutin	Anti-infective	Antimycobacterial	capsule
rifampin	Anti-infective	Antimycobacterial	capsule
rifapentine	Anti-infective	Antimycobacterial	tablet
rifaximin	Gastrointestinal	Anti-infective	tablet
risperidone	Central nervous system	Antipsychotic, atypical	tablet, oral liquid, injection
rivaroxaban	Blood formation and coagulation	Anticoagulant	tablet, oral liquid
rizatriptan	Central nervous system	Antimigraine	tablet
rosuvastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	capsule, tablet
sacubitril/valsartan	Cardiovascular	Neprilysin inhibitor/ARB	tablet
SARS-CoV-2 (COVID 19) vaccine	Vaccines	Viral vaccine	injection
semaglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	tablet, injection
sertraline	Central nervous system	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
sildenafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet, oral liquid
sitagliptin	Antidiabetic	Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor)	tablet
smallpox/monkeypox vaccine	Vaccines	Viral vaccine	injection
sofosbuvir/velpatasvir	Anti-infective	Hepatitis C antiviral	tablet, oral pellet packet

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****

CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
sofosbuvir/velpatasvir/voxilaprevir	Anti-infective	Hepatitis C antiviral	tablet
spironolactone	Cardiovascular	Potassium sparing diuretic	tablet, oral liquid
spironolactone/hydrochlorothiazide	Cardiovascular	Potassium sparing diuretic combinations	tablet
sucralfate	Gastrointestinal	Gastric acid buffer	tablet, oral liquid, mucosal paste
sulfadiazine	Anti-infective	Sulfonamide antibiotic	tablet
sulfamethoxazole/trimethoprim	Anti-infective	Sulfonamide antibiotic	tablet, oral liquid
sumatriptan	Central nervous system	Antimigraine	tablet, injection, nasal spray
tadalafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet, oral liquid
tamsulosin	Genitourinary	Alpha-blocker	capsule
terazosin	Cardiovascular	Alpha-blocker	capsule
terconazole	Anti-infective	Azole antifungal	topical, vaginal suppository
testosterone ^{CS}	Endocrine	Androgen	injection, gel, patch (<i>note: testosterone undecanoate is nonformulary</i>)
tetanus diphtheria (Td) vaccine	Vaccines	Bacterial vaccine	injection
tetanus diphtheria-acellular pertussis (Tdap) vaccine	Vaccines	Bacterial vaccine	injection
timolol	Antiglaucoma	Beta blocker	eye drops, tablet
tinidazole	Anti-infective	Amebicide, trichomonasicide	tablet
tiotropium	Respiratory	Anti-cholinergic, oral inhaled	inhaler
tiotropium/olodaterol	Respiratory	Long-acting muscarinic antagonist/long-acting Beta-2 agonist	inhaler
tizanidine	Central nervous system	Muscle relaxant	capsule, tablet
topiramate	Central nervous system	Anticonvulsant	capsule, tablet, oral liquid
tramadol ^{CS}	Analgesic	Opioid	capsule, tablet, oral liquid
travoprost	Antiglaucoma	Prostaglandin	eye drops
trazodone	Central nervous system, antidepressant	Serotonin reuptake inhibitor	tablet
tretinoin	Dermatologic	Anti-acne retinoid	capsule, topical
triamcinolone	Respiratory or Dermatologic	Corticosteroid	nasal spray, topical, oral paste
triamcinolone/nystatin	Dermatologic	Corticosteroid/antifungal	topical
triamterene/hydrochlorothiazide	Cardiovascular	Potassium sparing/thiazide diuretic	capsule
umeclidinium	Respiratory	Anticholinergic	inhaler
umeclidinium/vilanterol	Respiratory	Anticholinergic/long-acting Beta-2 agonist	inhaler
valacyclovir	Anti-infective	Antiherpetic antiviral	tablet
valganciclovir	Anti-infective	Antiherpetic antiviral (CMV)	tablet
valproic acid	Central nervous system	Anticonvulsant, mood stabilizer	capsule, oral liquid
valsartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet, oral liquid
valsartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
vancomycin	Anti-infective	Glycopeptide antibiotic	capsule, oral liquid
vardenafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet
varenicline	Smoking cessation	Partial nicotine agonist	tablet, nasal spray
venlafaxine	Central nervous system, antidepressant	Serotonin-norepinephrine reuptake inhibitor	capsule, tablet
verapamil	Cardiovascular	Calcium channel blocker	capsule, tablet
vitamin B complex	Vitamin	Vitamin	capsule, tablet
vitamin C	Vitamin	Vitamin	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary July 2026

****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****
^{CS} indicates controlled substance. ^{PA} indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
voriconazole	Anti-infective	Azole antifungal	tablet, oral liquid
warfarin	Blood formation and coagulation	Vitamin K antagonist	tablet
ziprasidone	Central nervous system	Antipsychotic, atypical	capsule, injection
zolpidem ^{CS}	Central nervous system	Sedative-hypnotic	capsule, tablet
zoster vaccine (recombinant)	Vaccines	Viral vaccine	injection

Due to recently added legislative language, the Florida Department of Health will expand the AIDS Drug Assistance Program (ADAP) Direct Dispense formulary.

Starting July 1, 2026, Biktarvy and Descovy will be restored to the ADAP formulary for all patients who are enrolled in direct dispense medication assistance.

Descovy will no longer require prior authorization.

All other current ART medications will continue to be available for all eligible ADAP patients.

Patients enrolled in the CVS Caremark (Retail Dispense Program) for co-pay and deductible assistance will continue to receive Biktarvy and Descovy.

Additional Information:

- When transitioning a patient to a new ART regimen, please refer to the guidelines from [Initiation of Antiretroviral Therapy | NIH](#).
-

Patient Assistance:

- If your patient does not qualify for ADAP assistance, have them contact their case manager. They may qualify for Partnership for Prescription Assistance and for other patient assistance programs.
 - There are over 180 programs offered by pharmaceutical companies that provide free or low-cost drugs for individuals who cannot afford to pay for them. Each program has specific eligibility criteria and coverage. Additional resources can be found here: [Florida Health - ADAP](#).
 - For patients who have questions regarding their Direct Dispense status, the Department's pharmacy benefit manager, Prime Therapeutics, can be contacted at 833-604-0925 to discuss options.
 - For any additional questions or patients who are impacted, seeking general resources and guidance, ADAP Help Desk can be contacted at 844-381-2327.
-



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

MAKE A DIFFERENCE IN HIV CARE IN MIAMI-DADE COUNTY!

The Miami-Dade HIV/AIDS Partnership

The official Ryan White Program Planning Council in Miami-Dade County and the Advisory Board for HIV/AIDS to the Miami-Dade County Mayor and Board of County Commissioners.



YOUR VOICE. YOUR COMMUNITY. REAL IMPACT.



Influence how more than
\$27 MILLION
in Ryan White funds
are used



Help improve HIV care
and support services for
9,000+ PEOPLE
living with HIV



Advise Miami-Dade County
leaders on HIV-related
issues and policies



Build leadership, policy
and community
engagement skills

OPEN SEATS ON THE PARTNERSHIP



5 RYAN WHITE CLIENT SEATS

For Ryan White Program Clients
who are not affiliated or employed
by a Ryan White Part A funded
service provider.



5 COMMUNITY & PROFESSIONAL SEATS

For people with HIV, service providers,
and community stakeholders with
experience, skills, and a commitment
to our community.



Your voice is needed. Your community counts.
Join us in making an impact!

BECOME A MEMBER IN 3 EASY STEPS

1

CONFIRM ELIGIBILITY

See requirements
to the right.

2

CONTACT US

Email us to learn more
and request an
application.

3

ENGAGE & SERVE

Meet with the Membership
Committee and start
making a difference!



For more information, contact:

mdcpartnership@behavioralscience.com

DO YOU QUALIFY?

If you answer "YES" to these
questions, you could qualify
for membership!



Are you a resident of
Miami-Dade County?



Are you a registered
voter in Miami-Dade County?

Note: Some seats for people with
HIV are exempt from this
requirement.



Can you volunteer
three to five hours
per month for
Partnership activities?



**THANK YOU
FOR YOUR SERVICE
TO PEOPLE WITH HIV!**

Be sure to bring a Ryan White
client to your next meeting!

COMMITTEE OPPORTUNITIES

Work with a dedicated team of volunteers on these Partnership committees
PEOPLE WITH HIV ARE ENCOURAGED TO JOIN!

**YOUR INTEREST.
YOUR IMPACT.
YOUR COMMUNITY.**

CARE & TREATMENT COMMITTEE



8

OPEN SEATS



4
PEOPLE
WITH HIV



4
GENERAL
MEMBERS

Allocate Ryan White funds, set priorities for
health and support services, and improve
care for people with HIV.

HOUSING COMMITTEE



7

OPEN SEATS



1
PEOPLE
WITH HIV



6
GENERAL
MEMBERS

Work with the City of Miami Housing Opportunities
for Persons with AIDS Program to address
housing challenges for people with HIV.

MEDICAL CARE SUBCOMMITTEE



8

OPEN SEATS



5
PEOPLE
WITH HIV



3
EXPERTISE-
SPECIFIC SEATS*

Oversee updates to medical treatment guidelines
and the Ryan White Prescription Drug Formulary.

*Examples: Physician, Pharmacist, Mental Health Professional

PREVENTION COMMITTEE



4

OPEN SEATS



4

PEOPLE
WITH HIV

Develop and monitor local Ending the HIV Epidemic
activities and mobilize community action on the
latest HIV prevention initiatives.

STRATEGIC PLANNING COMMITTEE



10

OPEN SEATS



5
PEOPLE
WITH HIV



5
GENERAL
MEMBERS

Develop and monitor the official HIV Prevention and
Care Integrated Plan and the State of HIV report.

COMMUNITY COALITION



4

OPEN SEATS



4

PEOPLE
WITH HIV

Recruit and train new members, share meals
and testimonials, and strengthen community
engagement.



For more information, contact:

mdcpartnership@behavioralscience.com



Your voice matters.

Help shape the future of HIV care and prevention
in Miami-Dade County.





MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



Partnership Report to Committees and Subcommittee June 1, 2026, Meeting

Revised June 3, 2026

Supporting documents related to motions in this report are available online *at the new URL:* partnershipmiami.org/partnership/#pshipreports1, or from Behavioral Science Research Corp. (BSR) staff at mdcpartnership@behavioralscience.com.

Visit www.partnershipmiami.org/calendars/ for details on future meetings.

Care and Treatment Committee

1. Motion to table the removal Biktarvy from the Ryan White Part A Prescription Drug Formulary, retroactive to March 1, 2026, for reconsideration by the Care and Treatment Committee, pending final ADAP funding legislation.
 2. Motion to accept the FY 2026 Ryan White Program Service Descriptions as presented for:
 - Mental Health Services and Substance Abuse Outpatient Care and Substance Abuse Services (Residential),
 - Oral Health Care Service Description,
 - AIDS Pharmaceutical Assistance (Local Pharmaceutical Assistance Program-LPAP),
 - Outpatient Ambulatory Health,
 - Emergency Financial Assistance,
 - Food Bank Services,
 - Medical Transportation,
 - Health Insurance,
 - Outreach, and
 - Medical Case Management, including Treatment Adherence.
 3. Motion to accept the FY 2026 Ryan White Program Oral Health Care Standards as presented.
 4. Motion to accept the FY 2026 Ryan White Program Letter of Medical Necessity for Continuous Glucose Monitors as presented; and the FY 2026 Ryan White Program Nutritional Assessment for Extension of Occurrences of Food Bank Services as presented.
 5. Motion to allocate 100% (\$387,372) of the FY 2026-27 Ryan White Part A Carryover request to Food Bank Services.
 6. Motion to allocate \$1,382,476 in FY 2026-27 Ryan White MAI carryover requests as 50% (\$691,238) to Medical Case Management and 50% (\$691,238) to Outpatient/Ambulatory Health Services.
-

Joint Integrated Plan Review Team (JIPRT)
(Strategic Planning Committee and Prevention Committee)

7. Motion to approve the final draft of the 2027-2031 Miami-Dade County Integrated Prevention and Care Plan in its substantially complete form, subject to final administrative edits.
8. Motion to approve the Letter of Concurrence as presented and to authorize the Partnership Chair to sign the letter.

Membership

9. Motion to appoint Rolando Hallmon to the Housing Committee.

New Business

10. Motion to authorize Harold McIntyre to sign the Health Resources & Services Administration (HRSA), HIV/AIDS Bureau (HAB), Division of Metropolitan HIV/AIDS Program Ryan White HIV/AIDS Program Part A Final Unobligated Balance Report and Final Carryover Request form.
 11. Motion to approve Rolando Hallmon to represent the Partnership at the 2026 Ryan White Conference.
 12. Motion to move the August Partnership meeting to Tuesday, August 11, 2026.
-



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

MIAMI-DADE COUNTY - RYAN WHITE PART A
FY 2026-27 (YR 36) FORMULA AND SUPPLEMENTAL FUNDING
SWEEPS 1 (SW1) - FUNDING REALLOCATION

YR 36 RANKING ORDER ¹	SERVICE CATEGORIES	CORE/SUPPORT	YR 36 ALLOCATIONS ²	SW1 PROPOSED REDUCTIONS	SW1 REQUESTS	SW1 FUNDING RECOMMENDATIONS ³
2	MEDICAL CASE MANAGEMENT	CORE	\$ 5,869,052	\$ (1,530,043)	\$ 1,932,000	\$ 5,469,962
3	AIDS PHARMACEUTICAL ASSISTANCE	CORE	\$ 88,255	\$ (84,881)		\$ 3,374
4	OUTPATIENT/AMBULATORY HEALTH SRVS.	CORE	\$ 8,847,707	\$ (1,506,536)	\$ 811,630	\$ 8,138,171
5	ORAL HEALTH CARE	CORE	\$ 3,088,975		\$ 1,640,542	\$ 4,343,517
6	HEALTH INSURANCE SERVICES	CORE	\$ 595,700	\$ (574,142)		\$ 21,558
7	MENTAL HEALTH SERVICES	CORE	\$ 132,385	\$ (64,011)	\$ 20,000	\$ 88,374
8	EMERGENCY FINANCIAL ASSISTANCE	SUPPORT	\$ 88,253	\$ (88,253)		\$ -
9	FOOD BANK	SUPPORT	\$ 529,539		\$ 751,860	\$ 1,281,399
10	MEDICAL TRANSPORTATION	SUPPORT	\$ 154,449	\$ (37,301)	\$ 115,000	\$ 232,148
12	SUBSTANCE ABUSE OUTPATIENT CARE	CORE	\$ 44,128	\$ (11,044)		\$ 33,084
13	OUTREACH SERVICES	SUPPORT	\$ 264,696	\$ (118,491)		\$ 146,205
14	SUBSTANCE ABUSE RESIDENTIAL	SUPPORT	\$ 2,169,744	\$ (548,400)	\$ 72,506	\$ 1,693,850
17	OTHER PROFESSIONAL SERVICES (LEGAL)	SUPPORT	\$ 154,449	\$ (130,449)		\$ 24,000
	SUBTOTAL		\$ 22,027,332	\$ (4,693,551)	\$ 5,343,538	\$ 21,475,642
	CLINICAL QUALITY MANAGEMENT		\$ 602,559			\$ 602,559
	ADMINISTRATION (10%) ⁴		\$ 2,407,248			\$ 2,407,248
	GRAND TOTAL		\$ 25,037,139	\$ (4,693,551)	\$ 5,343,538	\$ 24,485,449

FY 2026 (YR 36) Direct Services Allocations

Provisional Awards:	\$ 22,027,332
Available Funding for Direct Services:	\$ 21,088,270
Difference:	(\$939,062)

FY 2026 (YR 36) Final Award (Breakdown by Funding Source)

Formula Funding	\$ 16,023,875	
Supplemental Funding	\$ 8,074,202	
Carryover (Part A) - Pending HRSA award	\$ 387,372	\$ 24,485,449
MAI Funding	\$ 2,441,835	
Carryover (MAI) - Pending HRSA award	\$ 1,382,476	\$ 3,824,311
Total Award:	\$ 28,309,760	

NOTES:

¹ YR 36 ranking order is based on the Partnership's Needs Assessment allocation for FY 2026 which includes non-funded services. Please see attached for the complete list of prioritized core medical and support services for this jurisdiction.

² Provisional award letters currently include contract base amounts approved by the Board of County Commissioners through Resolution NO. R-246-20, as a result of RFP RW-DS-0320; and extended through February 28, 2027 under Resolution No. R-96-26. CORE Services Total = \$18,666,202 (85%); SUPPORT Services Total = \$3,361,130. (15%).

³ If the SW1 recommendations are adopted, the CORE Services Total = \$18,098,040 (86%); SUPPORT Services Total = \$2,990,230 (14%); CLINICAL QUALITY MANAGEMENT (3%). Please note, the Core/Support ratio does not include carryover funding.

⁴ Administration includes Partnership (Planning Council) and Program Support Costs.

MIAMI-DADE COUNTY RYAN WHITE PART A
FY 2026-27 (YR 36) MINORITY AIDS INITIATIVE (MAI)
SWEEPS 1 (SW1) - FUNDING REALLOCATION

YR 36 RANKING ORDER ¹	SERVICE CATEGORIES	CORE/SUPPORT	YR 36 ALLOCATIONS ²	SW1 PROPOSED REDUCTIONS	SW1 REQUESTS	SW1 FUNDING RECOMMENDATIONS ³
1	MEDICAL CASE MANAGEMENT	CORE	\$ 903,920		\$ 543,500	\$ 1,447,420
3	MENTAL HEALTH SERVICES	CORE	\$ 18,960			\$ 18,960
4	OUTPATIENT/AMBULATORY HEALTH SVS	CORE	\$ 1,362,753		\$ 580,493	\$ 1,943,246
5	MEDICAL TRANSPORTATION	SUPPORT	\$ 7,628		\$ 15,000	\$ 22,628
9	EMERGENCY FINANCIAL ASSISTANCE	SUPPORT	\$ 12,087	\$ (12,087)		\$ -
12	SUBSTANCE ABUSE OUTPATIENT CARE	CORE	\$ 8,058			\$ 8,058
21	OUTREACH SERVICES	SUPPORT	\$ 39,816			\$ 39,816
	SUBTOTAL		\$ 2,353,222	\$ (12,087)	\$ 1,138,993	\$ 3,480,128
	CLINICAL QUALITY MANAGEMENT		\$ 100,000			\$ 100,000
	ADMINISTRATION (10%)		\$ 244,183			\$ 244,183
	GRAND TOTAL		\$ 2,697,405	\$ (12,087)	\$ 1,138,993	\$ 3,824,311

FY 2026 (YR 36) Direct Services Allocations

Provisional Awards: \$ 2,353,222
Available Funding for Direct Services: **\$ 2,097,652**
Difference: **(\$255,570)**

FY 2026 (YR 36) Final Award (Breakdown by Funding Source)

Formula Funding	\$ 16,023,875		
Supplemental Funding	\$ 8,074,202		
Carryover (Part A) - Pending HRSA award	\$ 387,372		\$ 24,485,449
MAI Funding	\$ 2,441,835		
Carryover (MAI) - Pending HRSA award	\$ 1,382,476		\$ 3,824,311
Total Award:	\$ 28,309,760		

NOTES:

¹ YR 36 ranking order is based on the Partnership's Needs Assessment allocation for FY 2026 which includes non-funded services. Please see attached for the complete list of prioritized core medical and support services for this jurisdiction.

² Provisional award letters currently include contract base amounts approved by the Board of County Commissioners through Resolution No. R-246-20, as a result of RFP RW-DS-0320; and extended through February 28, 2027 under Resolution No. R-96-26. CORE Services Total = \$2,293,691 (97%); SUPPORT Services Total = \$59,531 (3%).

³ If the SW1 recommendations are adopted, the CORE Services Total = \$2,035,208 (97%); SUPPORT Services Total = \$62,444 (3%); CLINICAL QUALITY MANAGEMENT (4%). Please note, the Core/Support ratio does not include carryover funding.



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Ryan White Program Demographic Data Fiscal Year 2025


(3/1/25-2/28/26)

July 9, 2026

Presentation created by Behavioral Science Research Corp.




Total Number of Unduplicated Clients Between FY 2021 and FY 2025




Note: Unduplicated client counts are generated using Ryan White Program billed service utilization data. Thus, these client counts may differ from those of other reports that are generated using differing methodologies.


Number of **New** Clients Served Ryan White Program, FY 2021-2025



Miami-Dade Ryan White Program (FY 2025) and FDOH Prevalence (CY 2024) Comparison





Miami-Dade Ryan White Program (FY 2025) and FDOH Prevalence (CY 2024) Comparison




AGE

Age Distribution of New and Total Clients in Care Ryan White Program, FY 2025



Clients by Age Group

Ryan White Program, FY 2021-2025





■ <25	3%	2%	1%	2%	2%
■ 25 - 34	20%	21%	19%	20%	18%
■ 35 - 49	35%	35%	37%	37%	38%
■ 50 - 64	37%	36%	35%	35%	35%
■ 65+	5%	6%	8%	7%	7%


SEX



Sex Distribution of New and Total Clients in Care Ryan White Program, FY 2025



Sex of Clients in Care Ryan White Program, FY 2021-2025





RACE/ETHNICITY




Race/Ethnicity Distribution of New and Total Clients in Care

Ryan White Program, FY 2025



Race/Ethnicity of Clients in Care Ryan White Program, FY 2021-2025





Hispanic	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Black, non-Hispanic	63%	65%	66%	66%	65%
Haitian	20%	19%	18%	19%	19%
White, non-Hispanic	10%	9%	9%	10%	10%
Other	7%	6%	6%	6%	6%
	1%	1%	1%	1%	1%

RACE/ETHNICITY AND SEX




Race/Ethnicity by Sex of New and Total Clients in Care Ryan White Program, FY 2025



Race/Ethnicity of Clients in Care, by Sex

Ryan White Program, FY 2021-2025





PRIMARY MODE OF EXPOSURE



Primary Mode of Exposure

New and Total Clients in Care



Ryan White Program, FY 2025



MALE PRIMARY EXPOSURE MODES




Primary Mode of Exposure New and Total Males in Care Ryan White Program, FY 2025



Primary Mode of Exposure by Race/Ethnicity

Males in Care

Ryan White Program, FY 2025




■ Heterosexual	43.8%	79.5%	15.2%	11.6%
■ Injection Drug Use	0.5%	0.2%	0.4%	2.9%
■ Male to Male Sexual Contact	51.1%	16.3%	82.6%	82.1%
■ Male to Male Sexual Contact/IDU	0.4%	0.0%	0.2%	1.2%
■ Mother	1.2%	1.8%	0.2%	0.2%
■ Other	0.2%	0.5%	0.3%	0.2%
■ Unknown	2.8%	1.8%	1.1%	1.8%

Primary Mode of Exposure by Race/Ethnicity

Males **NEW** in Care

Ryan White Program, FY 2025



■ Heterosexual	34.2%	78.7%	18.8%	17.2%
■ Injection Drug Use	1.3%	0.0%	0.2%	1.2%
■ Male to Male Sexual Contact	57.6%	14.9%	78.0%	78.2%
■ Male to Male Sexual Contact/IDU	0.0%	0.0%	0.2%	0.0%
■ Mother	0.0%	0.0%	0.6%	0.0%
■ Other	0.0%	0.0%	0.4%	0.0%
■ Unknown	7.0%	6.4%	1.8%	3.5%



FEMALE PRIMARY EXPOSURE MODES



Primary Mode of Exposure

New and Total Females in Care


Ryan White Program, FY 2025



Primary Mode of Exposure by Race/Ethnicity

Females in Care

Ryan White Program, FY 2025




■ Heterosexual	94.9%	96.5%	94.4%	80.5%
■ Injection Drug Use	0.7%	0.0%	1.0%	7.3%
■ Mother with or at risk	2.5%	2.0%	1.4%	2.4%
■ Other	0.4%	0.9%	1.7%	4.9%
■ Unknown	1.5%	0.7%	1.5%	4.9%

Primary Mode of Exposure by Race/Ethnicity

Females **NEW** in Care

Ryan White Program, FY 2025





■ Heterosexual	93.3%	92.5%	90.3%	60.0%
■ Injection Drug Use	0.0%	0.0%	1.6%	0.0%
■ Mother with or at risk	1.7%	2.5%	3.2%	0.0%
■ Other	1.7%	0.0%	1.6%	20.0%
■ Unknown	3.3%	5.0%	3.2%	20.0%


PRIMARY LANGUAGE



Primary Language of New and Total Clients in Care Ryan White Program, FY 2025



Primary Language of Clients in Care Ryan White Program, FY 2021-2025




■ English	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
■ Spanish	33%	32%	30%	30%	31%
■ Haitian Creole	55%	57%	59%	58%	58%
■ Other	8%	8%	8%	9%	9%
	3%	3%	3%	3%	2%


INCOME LEVEL



Income Level of New and Total Clients in Care Ryan White Program, FY 2025



Income Level of Clients in Care Ryan White Program, FY 2021-2025




	0% - 135%	136% - 150%	151% - 200%	201% - 250%	251% - 300%	301% - 400%
FY 2025	51%	4%	13%	11%	9%	11%
FY 2024	47%	4%	15%	12%	10%	12%
FY 2023	49%	4%	14%	13%	10%	11%
FY 2022	49%	4%	14%	12%	9%	11%
FY 2021	51%	5%	13%	11%	9%	10%




INSURANCE COVERAGE

Insurance Coverage of New and Total Clients in Care Ryan White Program, FY 2025



Insurance Coverage of Clients in Care Ryan White Program, FY 2021-2025



Only RWHAP	51%	48%	45%	41%	39%
Medicaid	2%	4%	4%	4%	3%
Medicare	2%	4%	4%	4%	5%
ACA	34%	36%	38%	40%	31%
Private Ins	9%	10%	12%	14%	25%
VA	1%	1%	0%	0%	0%

*Thank
You*





MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Ryan White Program Co-Occurring Conditions Fiscal Year 2025

(3/1/25-2/28/26)

July 9, 2026

Presentation created by Behavioral Science Research Corp.





Disclaimers

- ▶ Based on data from Groupware Technology's Provide Enterprise-Miami database.
- ▶ Note: Unduplicated client counts are generated using Ryan White Program billed service utilization data. Thus, these client counts and service costs may differ from those of other reports that are generated using differing methodologies.


Definition of Terms

<136% FPL	Ryan White Program (RWP) clients with an income at or below 136% of the federal poverty level (FPL).
AIDS Dx	RWP clients with an AIDS diagnosis at any point in time.
No Health Insurance	RWP clients with no other forms of health insurance, including Medicare, Medicaid, VA benefits, private health insurance (including ACA), or employer-paid insurance
Mental Illness	RWP clients who received mental health counseling (through MHS or OAHS) and/or psychiatric services through OAHS in the designated fiscal year.
Substance Use Disorder	RWP clients with self-reported drug use in the past 12 months, currently report using injection drugs, have received RWP substance use disorder treatment in the designated fiscal year, or who attend AA/NA meetings.
Hepatitis B or C	RWP clients who have had a positive Hepatitis B or Hepatitis C lab test result within the last three (3) fiscal years.
STI	RWP clients who had a positive lab test result for either Syphilis, Gonorrhea, or Chlamydia during the designated fiscal year.
Homeless/Unstably Housed	RWP clients who reported having non-permanent housing (homeless, transient, or transition) and/or answered the question “With whom are you living?” with either “I am homeless” or “I live in a group home/shelter” during the designated fiscal year.
WoCA	Women of Child-Bearing Age—RWP female clients between the ages of 15 and 44.
VL	Viral Load
COC	Co-Occurring Conditions
ACA	Affordable Care Act

Group Parameters

- The are seven (6) Special Need Groups that the Miami-Dade County RWP looks at:
 - Substance Users
 - Black/African-American (BAA) males
 - Black/African-American (BAA) females
 - Women of Childbearing Age (WoCA)
 - Haitian males and females
 - Latino males
- The are eight (8) co-occurring conditions (COC) of interest to the Miami Dade County RWP:
 - Poverty (<136% of FPL)
 - No other forms of health insurance/coverage
 - AIDS diagnosis
 - Positive test for an STI (chlamydia, gonorrhea, and/or syphilis)
 - Positive test for Hepatitis B or C within past three years
 - Substance use
 - Mental illness
 - Being homeless or unstably housed.


Total Clients by Co-Occurring Condition, FY 2025



Treatment Costs by Co-Occurring Conditions

Co-Occurring Condition	FY 2025 RWP Clients w/ Co-Occurring Condition		Total Tx Cost (from PE Billed Service Detail Data)	Avg. Tx Cost per Client
	# of RW clients with COC	% of RW clients		
All RWP Clients	9,257	100%	\$25,406,724	\$2,745
<136% FPL	4,750	51%	\$14,909,750	\$3,139
No Health Ins.	3,642	39%	\$12,843,344	\$3,526
STI	2,390	26%	\$8,045,773	\$3,366
AIDS diagnosis	2,212	24%	\$6,140,904	\$2,776
Homeless/UH	649	7%	\$2,827,615	\$4,357
Substance Use	611	7%	\$2,686,486	\$4,397
Hepatitis B or C	533	6%	\$1,720,802	\$3,229
Mental Illness	399	4%	\$2,186,976	\$5,481

VL Suppression % by Co-Occurring Condition, FY 2025



Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%									88%
Latino Males	5,476 59%									90%
Black Males	1,173 13%									84%
Black Females	552 6%									82%
Haitians	897 10%									87%
WoCA, Age 15-44	508 5%									81%
Substance Users	611 7%									88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%								88%
Latino Males	5,476 59%	2,498 46%								90%
Black Males	1,173 13%	745 64%								84%
Black Females	552 6%	350 63%								82%
Haitians	897 10%	504 56%								87%
WoCA, Age 15-44	508 5%	311 61%								81%
Substance Users	611 7%	395 65%								88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%	3,642 39%							88%
Latino Males	5,476 59%	2,498 46%	1,940 35%							90%
Black Males	1,173 13%	745 64%	567 48%							84%
Black Females	552 6%	350 63%	228 41%							82%
Haitians	897 10%	504 56%	404 45%							87%
WoCA, Age 15-44	508 5%	311 61%	277 55%							81%
Substance Users	611 7%	395 65%	309 51%							88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%	3,642 39%	2,212 24%						88%
Latino Males	5,476 59%	2,498 46%	1,940 35%	1,062 19%						90%
Black Males	1,173 13%	745 64%	567 48%	309 26%						84%
Black Females	552 6%	350 63%	228 41%	210 38%						82%
Haitians	897 10%	504 56%	404 45%	367 41%						87%
WoCA, Age 15-44	508 5%	311 61%	277 55%	94 19%						81%
Substance Users	611 7%	395 65%	309 51%	122 20%						88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%	3,642 39%	2,212 24%	2,390 26%					88%
Latino Males	5,476 59%	2,498 46%	1,940 35%	1,062 19%	1,770 32%					90%
Black Males	1,173 13%	745 64%	567 48%	309 26%	354 30%					84%
Black Females	552 6%	350 63%	228 41%	210 38%	38 7%					82%
Haitians	897 10%	504 56%	404 45%	367 41%	65 7%					87%
WoCA, Age 15-44	508 5%	311 61%	277 55%	94 19%	41 8%					81%
Substance Users	611 7%	395 65%	309 51%	122 20%	225 37%					88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%	3,642 39%	2,212 24%	2,390 26%	533 6%				88%
Latino Males	5,476 59%	2,498 46%	1,940 35%	1,062 19%	1,770 32%	307 6%				90%
Black Males	1,173 13%	745 64%	567 48%	309 26%	354 30%	93 8%				84%
Black Females	552 6%	350 63%	228 41%	210 38%	38 7%	19 3%				82%
Haitians	897 10%	504 56%	404 45%	367 41%	65 7%	51 6%				87%
WoCA, Age 15-44	508 5%	311 61%	277 55%	94 19%	41 8%	13 3%				81%
Substance Users	611 7%	395 65%	309 51%	122 20%	225 37%	55 9%				88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%	3,642 39%	2,212 24%	2,390 26%	533 6%	611 7%			88%
Latino Males	5,476 59%	2,498 46%	1,940 35%	1,062 19%	1,770 32%	307 6%	324 6%			90%
Black Males	1,173 13%	745 64%	567 48%	309 26%	354 30%	93 8%	162 14%			84%
Black Females	552 6%	350 63%	228 41%	210 38%	38 7%	19 3%	33 6%			82%
Haitians	897 10%	504 56%	404 45%	367 41%	65 7%	51 6%	18 2%			87%
WoCA, Age 15-44	508 5%	311 61%	277 55%	94 19%	41 8%	13 3%	34 7%			81%
Substance Users	611 7%	395 65%	309 51%	122 20%	225 37%	55 9%	611 100%			88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%	3,642 39%	2,212 24%	2,390 26%	533 6%	611 7%	399 4%		88%
Latino Males	5,476 59%	2,498 46%	1,940 35%	1,062 19%	1,770 32%	307 6%	324 6%	155 3%		90%
Black Males	1,173 13%	745 64%	567 48%	309 26%	354 30%	93 8%	162 14%	64 5%		84%
Black Females	552 6%	350 63%	228 41%	210 38%	38 7%	19 3%	33 6%	42 8%		82%
Haitians	897 10%	504 56%	404 45%	367 41%	65 7%	51 6%	18 2%	72 8%		87%
WoCA, Age 15-44	508 5%	311 61%	277 55%	94 19%	41 8%	13 3%	34 7%	39 8%		81%
Substance Users	611 7%	395 65%	309 51%	122 20%	225 37%	55 9%	611 100%	66 11%		88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Incidence of Co-Occurring Conditions among Special Need Populations

SPECIAL NEEDS GROUPS	Total N	<136% FPL	No Health Ins.	Any AIDS Dx	STI	Hep B or C	Subs. Use	Mental Illness	Homeless/ Unstably Housed	VL Supp % of Special Needs Groups
Total RWP Clients	9,257 100%	4,750 51%	3,642 39%	2,212 24%	2,390 26%	533 6%	611 7%	399 4%	649 7%	88%
Latino Males	5,476 59%	2,498 46%	1,940 35%	1,062 19%	1,770 32%	307 6%	324 6%	155 3%	262 5%	90%
Black Males	1,173 13%	745 64%	567 48%	309 26%	354 30%	93 8%	162 14%	64 5%	201 17%	84%
Black Females	552 6%	350 63%	228 41%	210 38%	38 7%	19 3%	33 6%	42 8%	48 9%	82%
Haitians	897 10%	504 56%	404 45%	367 41%	65 7%	51 6%	18 2%	72 8%	47 5%	87%
WoCA, Age 15-44	508 5%	311 61%	277 55%	94 19%	41 8%	13 3%	34 7%	39 8%	39 8%	81%
Substance Users	611 7%	395 65%	309 51%	122 20%	225 37%	55 9%	611 100%	66 11%	185 30%	88%
VL Supp % of Clients	88%	85%	85%	87%	95%	90%	88%	92%	84%	

Summary of Findings

- Special Need Groups (SNG):
 - Latino Males (VL suppression 90%) represented the SNG with the highest VL suppression rate, higher than the overall RWP average.
 - Accounted for 59% of the total RWP population.
 - WoCA (Age 15-44) had the lowest VL suppression rate (81%).
- Co-Occurring Conditions (COC):
 - Clients with Sexually Transmitted Infections (STI) showed the highest VL suppression rate (95%).
 - Clients with Hepatitis B or C and clients with Mental Illness also had higher average VL suppression rates than the RWP average.
 - Clients who were Homeless/Unstably Housed had the lowest VL suppression rate (84%).
 - Clients with Mental Illness, Substance Use, and Homelessness/Unstable Housing COCs showed the highest annual costs per client, \$5,481, \$4,397, and \$4,357 respectively.

*Thank
You*



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Ryan White Needs Assessment Other Funding and Dashboard Cards

July 9, 2026

Presentation created by Behavioral Science Research Corp.



Today's Presentation

Ryan White Needs Assessment Dashboard Cards Overview

Trends, Dollars, and Utilization for All Direct Service Categories

July 9, 2026

Presentation created by Behavioral Science Research Corp.




Miami-Dade Medicaid HIV/AIDS Program

Details on a Funding Source for Dashboard

July 9, 2026

Presentation created by Behavioral Science Research Corp.



2026

RYAN WHITE PROGRAM NEEDS ASSESSMENT DASHBOARD CARDS

	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Total Expenditures	\$17,660,128	\$19,018,258	\$22,372,383	\$23,801,341	\$23,557,203	\$23,594,690
Total Unduplicated Clients	8,127	8,411	8,590	9,060	9,316	9,194
Total Average Cost/Client	\$2,173	\$2,261	\$2,604	\$2,627	\$2,529	\$2,566



PREPARED BY: Behavioral Science Research

The Why?

- ▶ Over the course of the Needs Assessment and priority setting meetings, we present a lot of data on service categories.
- ▶ By the time we get to the prioritization and allocation discussions, it can be very confusing.
- ▶ Dashboard Cards summarize critical data for each service category, from historical trends in utilization to expenditures and funding from other funding sources.
- ▶ Dashboard Card summaries are intended to guide your data-based decisions when setting priorities and estimating funding needs.

Other Ryan White Program Parts: What do they do?

Miami-Dade County providers represent four of the five Ryan White Program parts (A-F):

Part A: Core and support services provided throughout the Eligible Metropolitan Area (EMA) of Miami-Dade County administered by the Miami-Dade County Office of Management and Budget (“the Recipient”)

Part B: Services provided through the State of Florida and the AIDS Drug Assistance Program (ADAP)

Part C: Local Miami-Dade Community-Based Early Intervention Services

Part D: Miami-Dade County services to Women, Infants, Children and Youth (WICY)

Miami-Dade County Medicaid HIV/AIDS Expenditures FY 2024-25

Located in Tab 5 of the 2026
Needs Assessment book.

Miami-Dade County Medicaid HIV/AIDS
Expenditures FY 2024-2025

Bucket	Service	Recipients	Amount
01	HOSPITAL INPATIENT SERV	1,050	\$ 10,059,010.50
02	HOSPITAL INSURANCE BENE	434	\$ 1,126,659.78
03	HOSPITAL OUTPATIENT SER	3,094	\$ 4,131,554.08
04	HOSPITAL OUTPATIENT XOV	1,187	\$ 515,117.40
05	SKILLED NURSING XOVER	40	\$ 562,896.71
06	SKILLED NURSING CARE	160	\$ 6,399,378.80
07	INTERMEDIATE CARE	90	\$ 3,716,070.65
12	PHYSICIAN SERVICES	4,808	\$ 5,862,351.50
13	PHYSICIAN XOVER	1,535	\$ 511,198.55
14	PRESCRIBED MEDICINE	5,425	\$ 87,708,672.48
15	OTHER LAB AND X-RAY	3,163	\$ 887,968.51
16	LAB AND X-RAY XOVER	734	\$ 26,396.47
17	TRANSPORTATION	2,164	\$ 2,240,574.92
18	TRANSPORTATION XOVER	368	\$ 95,927.52
19	FAMILY PLANNING SERVICE	57	\$ 11,089.47
20	HOME HEALTH SERVICES	1,300	\$ 5,649,656.50
21	HOME HEALTH XOVER	246	\$ 38,666.92
22	EPSDT SCREENING	189	\$ 15,856.86
24	CHILD VISUAL SERVICES	28	\$ 4,207.24
27	ADULT VISUAL SERVICES	452	\$ 47,957.91
29	CASE MANAGEMENT-CMS	185	\$ 894,408.40
31	NURSE PRACTITIONER SERV	345	\$ 122,667.45
32	OTHER XOVER PRACTITIONE	670	\$ 68,775.63
33	HOSPICE	50	\$ 1,067,089.13
34	COMMUNITY MENTAL HLTH S	1,440	\$ 3,927,211.68
35	HCB-AGING	487	\$ 2,272,778.24
36	HCB-DEVELOPMENTAL SERVI	107	\$ 4,316,632.32
37	HCB-AIDS	177	\$ 631,373.70
39	PREPAID HEALTH PLAN	1,567	\$ 578,790.65
43	PRIVATE DUTY NURSING SE	35	\$ 1,304,181.19
44	PHYSICAL THERAPY SERVIC	192	\$ 164,443.65
45	SPEECH THERAPY SERVICES	17	\$ 69,971.02
46	OCCUPATIONAL THERAPY SE	17	\$ 61,487.06
49	FEDERALLY QUALIFIED CEN	1,197	\$ 243,196.72
53	CLINIC SERVICES	32	\$ 5,303.32
56	CASE MANAGEMENT-ADULT M	305	\$ 697,933.06
59	TSFC-COMMUNITY MENTAL H	91	\$ 214,566.64
62	PHYSICIAN ASSISTANT SER	828	\$ 84,055.96
64	SCHOOL BASED SERVICES	17	\$ 1,381.49
65	DIALYSIS CENTER	47	\$ 746,718.20
67	BRAIN & SPINAL CORD INJU	17	\$ 680,738.00
71	ASSISTIVE CARE SERVICES	97	\$ 1,270,415.91
72	HEALTHY START WAIVER	83	\$ 24,674.00
81	ADULT DAY CARE	62	\$ 726,994.70
95	APPLIED BEHAVIORAL ANALYSIS	35	\$ 987,247.35
-	OTHER	154	\$ 2,267,566.18
	Total	9,834	\$ 153,044,481.22

Miami-Dade County Medicaid HIV/AIDS Demographics FY 2022-23 to FY 2024-25

Located in Tab 5 of 2026
Needs Assessment book.

Miami-Dade County Medicaid HIV/AIDS Demographic Information FY 2022-FY 2025

	FY 2022-2023						FY 2023-2024						FY 2024-2025					
	Male	%	Female	%	Total	%	Male	%	Female	%	Total	%	Male	%	Female	%	Total	%
Black/African American	1,912	17.7%	2,657	24.6%	4,569	42.3%	2,029	18.0%	2,749	24.4%	4,778	42.5%	1,739	17.7%	2,390	24.3%	4,129	42.0%
Hispanic	2,122	19.6%	1,110	10.3%	3,232	29.9%	2,002	17.8%	1,195	10.6%	3,197	28.4%	1,250	12.7%	630	6.4%	1,880	19.1%
Not Determined	1,227	11.4%	775	7.2%	2,002	18.5%	1,326	11.8%	832	7.4%	2,158	19.2%	1,310	13.3%	829	8.4%	2,139	21.8%
Other	223	2.1%	115	1.1%	338	3.1%	245	2.2%	135	1.2%	380	3.4%	370	3.8%	334	3.4%	704	7.2%
Other (*less than 15 count)		0.0%		0.0%	16	0.1%		0.0%		0.0%	14	0.1%		0.0%		0.0%	15	0.2%
White	457	4.2%	191	1.8%	648	6.0%	485	4.3%	236	2.1%	721	6.4%	612	6.2%	355	3.6%	967	9.8%
TOTAL	5,941	55.0%	4,848	44.9%	10,805	100.0%	6,087	54.1%	5,147	45.8%	11,248	100.0%	5,281	53.7%	4,538	46.1%	9,834	100.0%

	FY 2022-2023						FY 2023-2024						FY 2024-2025					
	Male	%	Female	%	Total	%	Male	%	Female	%	Total	%	Male	%	Female	%	Total	%
Black/African American	1,784	17.2%	2,508	24.2%	4,292	41.4%	1,902	17.6%	2,594	24.0%	4,496	41.7%	1,623	17.3%	2,238	23.8%	3,861	41.1%
Hispanic	2,088	20.2%	1,059	10.2%	3,147	30.4%	1,965	18.2%	1,146	10.6%	3,111	28.8%	1,232	13.1%	609	6.5%	1,841	19.6%
Not Determined	1,197	11.6%	753	7.3%	1,950	18.8%	1,301	12.1%	801	7.4%	2,102	19.5%	1,281	13.6%	798	8.5%	2,079	22.2%
Other	218	2.1%	104	1.0%	322	3.1%	238	2.2%	125	1.2%	363	3.4%	355	3.8%	303	3.2%	658	7.0%
Other * (counts less than 15)		0.0%		0.0%	16	0.2%		0.0%		0.0%	14	0.1%		0.0%		0.0%	15	0.2%
White	450	4.3%	184	1.8%	634	6.1%	479	4.4%	223	2.1%	702	6.5%	597	6.4%	334	3.6%	931	9.9%
TOTAL	5,737	55.4%	4,608	44.5%	10,361	100.0%	5,885	54.6%	4,889	45.3%	10,788	100.0%	5,088	54.2%	4,282	45.6%	9,385	100.0%


	FY 2022-2023						FY 2023-2024						FY 2024-2025					
	Male	%	Female	%	Total	%	Male	%	Female	%	Total	%	Male	%	Female	%	Total	%
Black/African American	128	27.8%	149	32.4%	277	60.2%	127	28.3%	155	34.5%	282	62.8%	116	25.8%	152	33.9%	268	59.7%
Hispanic	34	7.4%	51	11.1%	85	18.5%	37	8.2%	49	10.9%	86	19.2%	18	4.0%	21	4.7%	39	8.7%
Not Determined	30	6.5%	22	4.8%	52	11.3%	25	5.6%	31	6.9%	56	12.5%	29	6.5%	31	6.9%	60	13.4%
Other		0.0%		0.0%		0.0%		0.0%		0.0%	0	0.0%	15	3.3%	31	6.9%	46	10.2%
Other (*less than 15 count)		0.0%		0.0%	30	6.5%		0.0%		0.0%	36	8.0%		0.0%		0.0%	0	0.0%
White		0.0%		0.0%		0.0%		0.0%		0.0%	0	0.0%	15	3.3%	21	4.7%	36	8.0%
TOTAL	192	41.7%	222	48.3%	444	96.5%	189	42.1%	235	52.3%	460	102.4%	193	43.0%	256	57.0%	449	100.0%

Medicaid Overview


Miami-Dade County Medicaid HIV/AIDS Expenses and Clients FY 2022 through FY 2024

	FY 2022	FY 2023	FY 2024
Expenses	\$429,525,001.62	\$363,957,239.75	\$153,044,481.22
Clients Served	10,805	11,248	9,834
Average annual cost per client	\$39,752.43	\$32,357.51	\$15,562.79

Miami-Dade County Total Medicaid Clients by Sex FY 2022-FY 2024




Miami-Dade County Total Medicaid Clients by Race/Ethnicity FY 2022- FY 2024



Comparison: Miami-Dade County Population (2024 Mid-year Estimate), Ryan White Program (FY 2025), FDOH Prevalence (CY 2024), and Medicaid(FY 2024)

Corrected

Miami-Dade County



2026

RYAN WHITE PROGRAM NEEDS ASSESSMENT DASHBOARD CARDS

	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Total Expenditures	\$17,660,128	\$19,018,258	\$22,372,383	\$23,801,341	\$23,557,203	\$23,594,690
Total Unduplicated Clients	8,127	8,411	8,590	9,060	9,316	9,194
Total Average Cost/Client	\$2,173	\$2,261	\$2,604	\$2,627	\$2,529	\$2,566



PREPARED BY: Behavioral Science Research

Total Number of Unduplicated Clients Served by Service Category (Alphabetic listing)

SERVICE CATEGORIES	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Ryan White Program TOTAL	8,127	8,411	8,590	9,060	9,316	9,194
AIDS Pharmaceutical Assistance (Local)	185	183	157	20	5	8
Emergency Financial Assistance	N/A	N/A	N/A	N/A	N/A	N/A
Food Bank	735	712	1,130	1,339	911	822
Health Insurance Premium & Cost Sharing Assist	1,125	1,255	1,440	1,699	1,926	2,254
Medical Case Management, inc. Treatment Adherence (includes Peer Support)	7,378	7,842	8,085	8,573	8,842	8,799
Medical Transportation Services	94	645	743	1,018	1,010	1,137
Mental Health Services	95	121	107	120	136	124
Oral Health Care	1,711	2,237	2,577	2,730	2,843	2,833
Other Professional Services - Legal Services and Permanency Planning	48	44	103	89	76	51
Outpatient/Ambulatory Health Services	4,281	4,422	4,540	4,547	4,577	4,220
Outreach Services	130	116	158	240	282	236
Substance Abuse Services Outpatient	0	17	22	10	9	4
Substance Abuse Services (Residential)	70	66	72	74	88	87

Service Category Sorted by Total Number of Unduplicated Clients in FY 2025

SERVICE CATEGORIES	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Ryan White Program TOTAL	8,127	8,411	8,590	9,060	9,316	9,194
Medical Case Management, inc. Treatment Adherence (includes Peer Support)	7,378	7,842	8,085	8,573	8,842	8,799
Outpatient/Ambulatory Health Services	4,281	4,422	4,540	4,547	4,577	4,220
Oral Health Care	1,711	2,237	2,577	2,730	2,843	2,833
Health Insurance Premium & Cost Sharing Assist	1,125	1,255	1,440	1,699	1,926	2,254
Medical Transportation Services	94	645	743	1,018	1,010	1,137
Food Bank	735	712	1,130	1,339	911	822
Outreach Services	130	116	158	240	282	236
Mental Health Services	95	121	107	120	136	124
Substance Abuse Services (Residential)	70	66	72	74	88	87
Other Professional Services - Legal Services and Permanency Planning	48	44	103	89	76	51
AIDS Pharmaceutical Assistance (Local)	185	183	157	20	5	8
Substance Abuse Services Outpatient	0	17	22	10	9	4
Emergency Financial Assistance	N/A	N/A	N/A	N/A	N/A	N/A

Total Expenditure by Service Category (Alphabetic Listing)

SERVICE CATEGORIES	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Ryan White Program TOTAL	8,127	8,411	8,590	9,060	9,316	9,194
CORE SERVICES						
AIDS Pharmaceutical Assistance (Local)	\$5,993	\$4,379	\$3,954	\$1,110	\$1,691	\$3,110
Health Insurance Premium & Cost Sharing Assistance	\$289,193	\$298,950	\$297,152	\$324,143	\$328,124	\$489,755
Medical Case Management, inc. Treatment Adherence (includes Peer Support)	\$5,283,942	\$5,744,512	\$6,030,823	\$6,510,077	\$6,615,778	\$7,413,360
Mental Health Services	\$90,019	\$60,239	\$64,577	\$59,426	\$56,518	\$52,618
Oral Health Care	\$1,645,879	\$2,533,062	\$3,273,644	\$3,631,549	\$3,974,346	\$4,513,801
Outpatient/Ambulatory Health Services	\$7,397,592	\$7,729,584	\$8,724,251	\$8,788,808	\$8,756,675	\$7,694,609
Substance Abuse Services Outpatient	\$23,556	\$1,356	\$4,971	\$1,440	\$1,560	\$780
SUPPORT SERVICES						
Emergency Financial Assistance	N/A	N/A	N/A	N/A	N/A	N/A
Food Bank	\$1,303,702	\$1,338,778	\$2,540,864	\$2,702,230	\$1,767,470	\$1,488,717
Medical Transportation	\$5,642	\$100,956	\$159,552	\$198,897	\$217,982	\$236,510
Other Professional Services - Legal Services and Permanency Planning	\$146,336	\$97,371	\$67,581	\$71,730	\$34,290	\$17,559
Outreach Services	\$148,155	\$140,761	\$151,423	\$153,681	\$163,019	\$161,871
Substance Abuse Services (Residential)	\$1,320,120	\$968,310	\$1,053,590	\$1,358,250	\$1,639,750	\$1,522,000

Service Category Sorted by FY 2025 Expenditure

SERVICES CATEGORIES	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	2025
Ryan White Program TOTAL	8,127	8,411	8,590	9,060	9,316	9,194
CORE SERVICES						
Outpatient/Ambulatory Health Services	\$7,397,592	\$7,729,584	\$8,724,251	\$8,788,808	\$8,756,675	\$7,694,609
Medical Case Management, inc. Treatment Adherence (includes Peer Support)	\$5,283,942	\$5,744,512	\$6,030,823	\$6,510,077	\$6,615,778	\$7,413,360
Oral Health Care	\$1,645,879	\$2,533,062	\$3,273,644	\$3,631,549	\$3,974,346	\$4,513,801
Health Insurance Premium & Cost Sharing Assistance	\$289,193	\$298,950	\$297,152	\$324,143	\$328,124	\$489,755
Mental Health Services	\$90,019	\$60,239	\$64,577	\$59,426	\$56,518	\$52,618
AIDS Pharmaceutical Assistance (Local)	\$5,993	\$4,379	\$3,954	\$1,110	\$1,691	\$3,110
Substance Abuse Services Outpatient	\$23,556	\$1,356	\$4,971	\$1,440	\$1,560	\$780
SUPPORT SERVICES						
Food Bank	\$1,303,702	\$1,338,778	\$2,540,864	\$2,702,230	\$1,767,470	\$1,488,717
Substance Abuse Services (Residential)	\$1,320,120	\$968,310	\$1,053,590	\$1,358,250	\$1,639,750	\$1,522,000
Medical Transportation	\$5,642	\$100,956	\$159,552	\$198,897	\$217,982	\$236,510
Outreach Services	\$148,155	\$140,761	\$151,423	\$153,681	\$163,019	\$161,871
Other Professional Services - Legal Services and Permanency Planning	\$146,336	\$97,371	\$67,581	\$71,730	\$34,290	\$17,559
Emergency Financial Assistance	N/A	N/A	N/A	N/A	N/A	N/A

CORE SERVICE: AIDS PHARMACEUTICAL ASSISTANCE

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	0.300%
FY 2021	\$19,018,258.46	0.020%
FY 2022	\$22,372,383.35	0.020%
FY 2023	\$23,801,341.37	0.005%
FY 2024	\$23,557,202.81	0.007%
FY 2025	\$23,594,690.18	0.013%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	\$66,007.00	\$5,993.21	9.08%
FY 2021	\$83,595.00	\$4,379.02	5.24%
FY 2022	\$84,492.00	\$3,954.10	4.68%
FY 2023	\$3,455.00	\$1,109.57	32.11%
FY 2024	\$7,679.00	\$1,691.22	22.02%
FY 2025	\$5,744.00	\$3,110.33	54.15%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	3	\$66,007.00	\$5,993.21	9.08%
FY 2021	9	\$83,595.00	\$4,379.02	5.24%
FY 2022	4	\$84,492.00	\$3,954.10	4.68%
FY 2023	3	\$3,455.00	\$1,109.57	32.11%
FY 2024	8	\$7,679.00	\$1,691.22	22.02%
FY 2025	5	\$5,744.00	\$3,110.33	54.15%



Notes:

FY 2025 total clients continue to decline and the continued uncertainty with ADAP issues maybe of concern in 2027.

CORE SERVICE: AIDS PHARMACEUTICAL ASSISTANCE

Service Program

Limitations: 400% FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	185	2.3%	\$5,993	\$32
FY 2021	8,420	183	2.17%	\$4,379	\$24
FY 2022	8,590	156	1.8%	\$3,954	\$25
FY 2023	9,060	20	0.22%	\$1,110	\$56
FY 2024	9,316	5	0.05%	\$1,691	\$338
FY 2025	9,194	8	0.09%	\$3,110	\$389

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost per Client
1	ADAP	\$15,278,371	4,864	\$3,141
2	General Revenue	\$95,195	160	\$595
3	Medicaid	\$99,541,969	6,720	\$14,813
4	Part C	\$36,186	N/A	N/A

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost per Client
1	ADAP	\$14,362,871	5,295	\$2,713
2	General Revenue	\$243,116	158	\$1,539
3	Medicaid	\$87,708,672	5,425	\$16,167
4	Part C	\$31,298	N/A	N/A
5	Other	\$5,200	2	\$2,600

SUPPORT SERVICE: EMERGENCY FINANCIAL ASSISTANCE

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	0%
FY 2021	\$19,018,258.46	0%
FY 2022	\$22,372,383.35	0%
FY 2023	\$23,801,341.37	0%
FY 2024	\$23,557,202.81	0%
FY 2025	\$23,594,690.18	0%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	N/A	N/A	N/A
FY 2021	N/A	N/A	N/A
FY 2022	N/A	N/A	N/A
FY 2023	N/A	N/A	N/A
FY 2024	N/A	N/A	N/A
FY 2025	N/A	N/A	N/A

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	12	N/A	N/A	N/A
FY 2021	12	N/A	N/A	N/A
FY 2022	11	N/A	N/A	N/A
FY 2023	4	N/A	N/A	N/A
FY 2024	12	N/A	N/A	N/A
FY 2025	14	N/A	N/A	N/A

Fiscal Year	MAI Ranking	MAI Final Allocation	MAI Final Expenditure	% Spent
FY 2020	7	N/A	N/A	N/A
FY 2021	7	N/A	N/A	N/A
FY 2022	7	N/A	N/A	N/A
FY 2023	6	N/A	N/A	N/A
FY 2024	5	N/A	N/A	N/A
FY 2025	8	N/A	N/A	N/A

Notes:

No expenditures have been made in this category, since Test and Treat Rapid Access (TTRA) funds have not been exhausted by the Department of Health.

SUPPORT SERVICE: EMERGENCY FINANCIAL ASSISTANCE

Service Program

Limitations: 400% FPL; limited to prescriptions drugs if TTRA funds are depleted.

Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	NA	NA	NA	NA
FY 2021	8,420	NA	NA	NA	NA
FY 2022	8,590	NA	NA	NA	NA
FY 2023	9,060	NA	NA	NA	NA
FY 2024	9,316	NA	NA	NA	NA
FY 2025	9,194	NA	NA	NA	NA

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$175,086	178	\$984
2	Part B	\$496,232	879	\$565
3	Part C	\$132,293	78	\$1,696

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$76,446	27	\$2,831
2	Part B	\$360,690	1318	\$274

SUPPORT SERVICE: FOOD BANK

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	7.38%
FY 2021	\$19,018,258.46	7.04%
FY 2022	\$22,372,383.35	11.36%
FY 2023	\$23,801,341.37	11.35%
FY 2024	\$23,557,202.81	7.50%
FY 2025	\$23,594,690.18	6.31%

Fiscal Year	Ranking	Final Allocation	Final Expenditure	% Spent
FY 2020	8	\$1,303,799.00	\$1,303,702.40	99.99%
FY 2021	5	\$1,385,995.00	\$1,338,778.40	96.59%
FY 2022	8	\$2,660,108.00	\$2,540,864.00	95.52%
FY 2023	7	\$2,702,342.00	\$2,702,229.90	100.00%
FY 2024	5	\$1,767,742.00	\$1,767,470.45	99.98%
FY 2025	6	\$1,488,861.00	\$1,488,717.20	99.99%



Notes:

FY 2025 expenditures and clients served continue to decrease from FY 2024 with limitation of FPL; clients at 251-400% FPL are accessing Part B assistance.

SUPPORT SERVICE: FOOD BANK

Service Program

Limitations: 250% FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	735	9.0%	\$1,303,702	\$1,774
FY 2021	8,420	712	8.5%	\$1,338,778	\$1,880
FY 2022	8,590	1,130	13.2%	\$2,540,864	\$2,249
FY 2023	9,060	1,339	14.8%	\$2,702,230	\$2,018
FY 2024	9,316	911	9.8%	\$1,767,470	\$1,940
FY 2025	9,194	822	8.9%	\$1,488,717	\$1,811

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost per Client
1	General Revenue	\$38,085	318	\$120
2	Other	\$16,485	336	\$49
3	Part D	\$11,231	271	\$41

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost per Client
1	General Revenue	\$39,038	211	\$185
2	Part D	\$9,567	361	\$27

CORE SERVICE: HEALTH INSURANCE

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	1.64%
FY 2021	\$19,018,258.46	1.57%
FY 2022	\$22,372,383.35	1.33%
FY 2023	\$23,801,341.37	1.36%
FY 2024	\$23,557,202.81	1.39%
FY 2025	\$23,594,690.18	2.08%

Fiscal Year	Ranking	Final Allocation	Final Expenditure	% Spent
FY 2020	5	\$459,450.00	\$289,193.00	62.94%
FY 2021	6	\$442,447.00	\$298,950.41	67.57%
FY 2022	6	\$595,700.00	\$297,151.61	49.88%
FY 2023	8	\$358,700.00	\$324,143.01	90.37%
FY 2024	6	\$328,454.00	\$328,123.61	99.90%
FY 2025	9	\$490,526.00	\$489,755.12	99.84%



Notes:

FY 2025 reflects the highest expenditures and clients in the last six years with the AIDS Drug Assistance Program (ADAP) program paying for ADAP eligible clients' premiums. But with the ADAP changes at the start of 2026, there will be a marked decrease in the number of clients served in this category.

CORE SERVICE: HEALTH INSURANCE

Service Program

Limitations: 400% FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	1,125	13.8%	\$289,193	\$257
FY 2021	8,420	1,225	14.5%	\$298,950	\$244
FY 2022	8,590	1,454	16.9%	\$297,152	\$204
FY 2023	9,060	1,699	18.8%	\$324,143	\$191
FY 2024	9,316	1,926	20.7%	\$328,124	\$170
FY 2025	9,194	2,254	24.5%	\$489,755	\$217

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	ADAP	\$57,729,746	3,705	\$15,582
2	Medicaid	\$167,336,187	12,639	\$13,240

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	ADAP	\$55,861,518	3,116	\$17,927
2	Medicaid	\$578,791	1,567	\$369

CORE SERVICE: MEDICAL CASE MANAGEMENT

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	29.92%
FY 2021	\$19,018,258.46	30.21%
FY 2022	\$22,372,383.35	26.96%
FY 2023	\$23,801,341.37	27.35%
FY 2024	\$23,557,202.81	28.08%
FY 2025	\$23,594,690.18	31.42%

Fiscal Year	Total Final Allocation	Final Expenditure	% Spent
FY 2020	\$6,901,831.00	\$5,283,941.69	76.56%
FY 2021	\$6,825,797.00	\$5,744,512.45	84.16%
FY 2022	\$7,130,657.00	\$6,030,822.85	84.58%
FY 2023	\$7,047,586.00	\$6,510,077.00	92.37%
FY 2024	\$7,075,147.00	\$6,615,778.20	93.51%
FY 2025	\$7,654,519.00	\$7,413,360.25	96.85%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	1	\$5,745,493.00	\$4,932,874.00	85.86%
FY 2021	1	\$5,921,877.00	\$5,094,347.45	86.03%
FY 2022	1	\$6,226,737.00	\$5,414,520.00	86.96%
FY 2023	2	\$5,979,259.00	\$5,864,806.80	98.09%
FY 2024	1	\$6,063,727.00	\$5,826,068.45	96.08%
FY 2025	2	\$6,377,000.00	\$6,313,337.80	99.00%

Fiscal Year	MAI Ranking	MAI Final Allocation	MAI Final Expenditure	% Spent
FY 2020	1	\$1,156,338.00	\$351,067.69	30.36%
FY 2021	1	\$903,920.00	\$650,165.00	71.93%
FY 2022	1	\$903,920.00	\$616,302.85	68.18%
FY 2023	1	\$1,068,327.00	\$645,270.20	60.40%
FY 2024	1	\$1,011,420.00	\$789,709.75	78.08%
FY 2025	1	\$1,277,519.00	\$1,100,022.45	86.11%



Notes:

While slightly fewer clients were served, overall 95.7% of Ryan White clients accessed this service and FY 2025 had the highest expenditures in six years.

CORE SERVICE: MEDICAL CASE MANAGEMENT

Service Program

Limitations: 400% FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	7,378	90.8%	\$5,283,942	\$716
FY 2021	8,420	7,842	93.1%	\$5,744,512	\$733
FY 2022	8,590	8,085	94.1%	\$6,030,823	\$746
FY 2023	9,060	8,573	94.6%	\$6,510,077	\$759
FY 2024	9,316	8,842	94.9%	\$6,635,939	\$751
FY 2025	9,194	8,799	95.7%	\$7,413,360	\$843

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$10,946	1,895	\$6
2	Medicaid	\$1,159,478	494	\$2,347
3	Part B	\$111,527	652	\$171
4	Part C	\$163,238	423	\$386
5	Part D	\$97,312	140	\$695

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$10,334	1,860	\$6
2	Medicaid	\$1,592,341	490	\$3,250
3	Part B	\$129,065	766	\$168
4	Part C	\$203,290	1,432	\$142
5	Part D	\$74,485	253	\$294

SUPPORT SERVICE: MEDICAL TRANSPORTATION

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	0.03%
FY 2021	\$19,018,258.46	0.53%
FY 2022	\$22,372,383.35	0.71%
FY 2023	\$23,801,341.37	0.84%
FY 2024	\$23,557,202.81	0.93%
FY 2025	\$23,594,690.18	1.00%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	\$158,277.00	\$5,641.90	3.56%
FY 2021	\$158,316.00	\$100,955.62	63.77%
FY 2022	\$217,540.00	\$159,552.49	73.34%
FY 2023	\$203,947.00	\$198,897.18	97.52%
FY 2024	\$269,582.00	\$217,981.99	80.86%
FY 2025	\$237,516.00	\$236,510.24	99.58%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	10	\$150,649.00	\$5,641.90	3.75%
FY 2021	10	\$150,688.00	\$98,584.06	65.42%
FY 2022	10	\$209,912.00	\$153,904.90	73.32%
FY 2023	13	\$196,319.00	\$191,280.78	97.43%
FY 2024	13	\$253,654.00	\$205,493.46	81.01%
FY 2025	10	\$222,888.00	\$222,229.06	99.70%

Fiscal Year	MAI Ranking	MAI Final Allocation	MAI Final Expenditure	% Spent
FY 2020	4	\$7,628.00	\$0.00	0.00%
FY 2021	4	\$7,628.00	\$2,371.56	31.09%
FY 2022	4	\$7,628.00	\$5,647.59	74.04%
FY 2023	9	\$7,628.00	\$7,616.40	99.85%
FY 2024	13	\$15,928.00	\$12,488.53	78.41%
FY 2025	7	\$14,628.00	\$14,281.18	97.63%



Notes:

Medical transportation clients and expenditures for FY 2025 are highest in the last six years.

SUPPORT SERVICE: MEDICAL TRANSPORTATION

Service Program

Limitations: 400% FPL; public transit passes or ride-share options



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	94	1.2%	\$5,642	\$60
FY 2021	8,420	645	7.7%	\$100,956	\$157
FY 2022	8,590	727	8.5%	\$159,552	\$219
FY 2023	9,060	1,018	11.2%	\$198,897	\$195
FY 2024	9,316	1,010	10.8%	\$217,982	\$216
FY 2025	9,194	1,137	12.4%	\$236,510	\$208

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$78,502	318	\$247
2	Medicaid	\$2,370,394	3,426	\$692
3	Part C	\$137,526	315	\$437
4	Part D	\$17,666	190	\$93

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$105,801	386	\$274
2	Medicaid	\$2,336,502	2,532	\$923
3	Part D	\$15,260	156	\$98

CORE SERVICE: MENTAL HEATH

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	0.51%
FY 2021	\$19,018,258.46	0.32%
FY 2022	\$22,372,383.35	0.29%
FY 2023	\$23,801,341.37	0.25%
FY 2024	\$23,557,202.81	0.24%
FY 2025	\$23,594,690.18	0.22%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	\$142,217.00	\$90,019.31	63.30%
FY 2021	\$169,464.00	\$60,238.75	35.55%
FY 2022	\$161,654.00	\$64,577.50	39.95%
FY 2023	\$80,730.00	\$59,426.25	73.61%
FY 2024	\$88,461.00	\$56,517.50	63.89%
FY 2025	\$73,263.00	\$52,617.50	71.82%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	4	\$123,257.00	\$82,435.31	66.88%
FY 2021	3	\$150,504.00	\$56,566.25	37.58%
FY 2022	3	\$142,694.00	\$63,570.00	44.55%
FY 2023	9	\$61,770.00	\$56,046.25	90.73%
FY 2024	3	\$69,501.00	\$53,527.50	77.02%
FY 2025	7	\$54,303.00	\$52,617.50	96.90%

Fiscal Year	MAI Ranking	MAI Final Allocation	MAI Final Expenditure	% Spent
FY 2020	3	\$18,960.00	\$7,584.00	40.00%
FY 2021	3	\$18,960.00	\$3,672.50	19.37%
FY 2022	3	\$18,960.00	\$1,007.50	5.31%
FY 2023	4	\$18,960.00	\$3,380.00	17.83%
FY 2024	3	\$18,960.00	\$2,990.00	15.77%
FY 2025	6	\$18,960.00	\$0.00	0.00%



Notes:

Client utilization has decreased to FY 2023 levels, and expenditures are the lowest in the last six years.

CORE SERVICE: MENTAL HEATH

Service Program

Limitations: 400% FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	95	1.2%	\$90,019.31	\$948
FY 2021	8,420	121	1.4%	\$60,238.75	\$498
FY 2022	8,590	101	1.2%	\$64,577.50	\$639
FY 2023	9,060	120	1.3%	\$59,426.00	\$495
FY 2024	9,316	136	1.5%	\$56,517.50	\$416
FY 2025	9,194	124	1.3%	\$52,618.00	\$424

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$73,351	177	\$414
2	Medicaid	\$3,967,662	1,568	\$2,530
3	Other	\$1,114,204	243	\$4,585
4	Part B	\$25,000	226	\$111
5	Part C	\$35,235	643	\$55
6	Part D	\$157,060	202	\$778

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$74,994	211	\$355
2	Medicaid	\$4,141,778	1,531	\$2,705
3	Other	\$893,027	198	\$4,510
4	Part C	\$197,668	857	\$231

CORE SERVICE: ORAL HEALTH CARE

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	9.32%
FY 2021	\$19,018,258.46	13.32%
FY 2022	\$22,372,383.35	14.63%
FY 2023	\$23,801,341.37	0.00%
FY 2024	\$23,557,202.81	16.87%
FY 2025	\$23,594,690.18	19.13%

Fiscal Year	Ranking	Final Allocation	Final Expenditure	% Spent
FY 2020	6	\$2,888,975.00	\$1,645,878.57	56.97%
FY 2021	4	\$3,108,975.00	\$2,533,061.80	81.48%
FY 2022	5	\$3,864,445.00	\$3,273,644.50	84.71%
FY 2023	6	\$3,701,975.00	\$3,631,549.00	98.10%
FY 2024	4	\$4,082,857.00	\$3,974,346.00	97.34%
FY 2025	4	\$4,631,775.00	\$4,513,801.00	97.45%



Notes:

Client utilization is similar to FY 2024 levels but expenditures have increased substantially.

CORE SERVICE: ORAL HEALTH CARE

Service Program

Limitations: 400% FPL; annual \$6,500 cap reinstated



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	1,711	21.1%	\$1,645,879	\$962
FY 2021	8,420	2,237	26.6%	\$2,533,062	\$1,132
FY 2022	8,590	2,575	30.0%	\$3,273,645	\$1,271
FY 2023	9,060	2,730	30.1%	\$3,631,549	\$1,330
FY 2024	9,316	2,843	30.5%	\$3,974,346	\$1,398
FY 2025	9,194	2,833	30.8%	\$4,513,801	\$1,593

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$7,061	39	\$181
2	Other	\$364,257	167	\$2,181
3	Part C	\$228,544	458	\$499

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$12,855	14	\$918
2	Other	\$402,759	169	\$2,383
3	Part C	\$134,986	N/A	N/A

SUPPORT SERVICE: OTHER PROFESSIONAL SERVICES-LEGAL SERVICES AND PERMANENCY PLANNING

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	0.83%
FY 2021	\$19,018,258.46	0.51%
FY 2022	\$22,372,383.35	0.30%
FY 2023	\$23,801,341.37	0.30%
FY 2024	\$23,557,202.81	0.15%
FY 2025	\$23,594,690.18	0.07%

Fiscal Year	Ranking	Final Allocation	Final Expenditure	% Spent
FY 2020	13	\$154,449.00	\$146,335.50	94.75%
FY 2021	13	\$154,449.00	\$97,371.00	63.04%
FY 2022	13	\$154,449.00	\$67,581.00	43.76%
FY 2023	15	\$97,449.00	\$71,730.00	73.61%
FY 2024	15	\$40,274.00	\$34,290.00	85.14%
FY 2025	15	\$18,700.00	\$17,559.00	93.90%



Notes:

Client utilization and expenditures in FY 2025 continue to drop, with expenditures at the lowest level in six years.

SUPPORT SERVICE: OTHER PROFESSIONAL SERVICES-LEGAL SERVICES AND PERMANENCY PLANNING

Service Program

Limitations: 400 % FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	48	0.6%	\$146,336	\$3,049
FY 2021	8,420	44	0.5%	\$97,371	\$2,213
FY 2022	8,590	78	0.9%	\$67,581	\$866
FY 2023	9,060	89	1.0%	\$71,730	\$806
FY 2024	9,316	76	0.8%	\$34,290	\$451
FY 2025	9,194	51	0.6%	\$17,559	\$344

CORE SERVICE: OUTPATIENT/AMBULATORY HEALTH SERVICES

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	41.89%
FY 2021	\$19,018,258.46	40.64%
FY 2022	\$22,372,383.35	39.00%
FY 2023	\$23,801,341.37	36.93%
FY 2024	\$23,557,202.81	37.17%
FY 2025	\$23,594,690.18	32.61%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	\$10,153,862.00	\$7,397,591.74	72.85%
FY 2021	\$10,010,471.00	\$7,729,583.99	77.21%
FY 2022	\$10,652,424.00	\$8,724,251.44	81.90%
FY 2023	\$9,462,556.00	\$8,788,808.41	92.88%
FY 2024	\$9,757,911.00	\$8,756,674.98	89.74%
FY 2025	\$8,727,482.00	\$7,694,608.52	88.17%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final	% Spent
FY 2020	2	\$8,661,870.00	\$6,911,704.73	79.79%
FY 2021	2	\$8,647,718.00	\$7,268,815.93	84.05%
FY 2022	2	\$9,295,763.00	\$8,063,884.64	86.75%
FY 2023	5	\$7,940,909.00	\$7,848,156.83	98.83%
FY 2024	2	\$8,020,778.00	\$7,820,124.65	97.50%
FY 2025	3	\$7,007,729.00	\$6,971,950.08	99.49%

Fiscal Year	MAI Ranking	MAI Final Allocation	MAI Final Expenditure	% Spent
FY 2020	2	\$1,491,992.00	\$485,887.01	32.57%
FY 2021	2	\$1,362,753.00	\$460,768.06	33.81%
FY 2022	2	\$1,356,661.00	\$660,366.80	48.68%
FY 2023	5	\$1,521,647.00	\$940,651.58	61.82%
FY 2024	2	\$1,737,133.00	\$936,550.33	53.91%
FY 2025	3	\$1,719,753.00	\$722,658.44	42.02%



Notes:

There has been a marked decrease in clients served and expenditures in FY 2025.

CORE SERVICE: OUTPATIENT/AMBULATORY HEALTH SERVICES

Service Program

Limitations: 400% FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	4,281	52.7%	\$7,397,592	\$1,728
FY 2021	8,420	4,422	52.5%	\$7,729,584	\$1,748
FY 2022	8,590	4,506	52.5%	\$8,724,251	\$1,936
FY 2023	9,060	4,547	50.2%	\$8,788,808	\$1,933
FY 2024	9,316	4,577	49.1%	\$8,756,675	\$1,913
FY 2025	9,194	4,220	45.9%	\$7,694,609	\$1,823

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost per client
1	General Revenue	\$914,929	3,678	\$249
2	Medicaid	\$14,773,258	19,500	\$758
3	Other	\$1,280,170	2,077	\$616
4	Part C	\$1,215,944	3,597	\$338
5	Part D	\$743,233	1,267	\$587

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost per client
1	General Revenue	\$788,275	1,782	\$442
2	Medicaid	\$12,458,586	17,563	\$709
3	Other	\$1,618,920	2,143	\$755
4	Part C	\$992,567	3,442	\$288
5	Part D	\$685,978	786	\$873

SUPPORT SERVICE: OUTREACH SERVICES

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	0.84%
FY 2021	\$19,018,258.46	0.74%
FY 2022	\$22,372,383.35	0.68%
FY 2023	\$23,801,341.37	0.65%
FY 2024	\$23,557,202.81	0.69%
FY 2025	\$23,594,690.18	0.69%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	\$304,512.00	\$148,154.86	48.65%
FY 2021	\$212,096.00	\$140,761.02	66.37%
FY 2022	\$217,902.00	\$151,422.86	69.49%
FY 2023	\$189,097.00	\$153,681.05	81.27%
FY 2024	\$188,848.00	\$163,018.86	86.32%
FY 2025	\$180,477.00	\$161,871.02	89.69%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	11	\$264,696.00	\$118,293.86	44.69%
FY 2021	11	\$172,280.00	\$104,263.02	60.52%
FY 2022	12	\$178,086.00	\$114,924.86	64.53%
FY 2023	14	\$149,281.00	\$117,183.05	78.50%
FY 2024	14	\$149,032.00	\$123,202.86	82.67%
FY 2025	13	\$140,661.00	\$122,055.02	86.77%

Fiscal Year	MAI Ranking	MAI Final Allocation	MAI Final Expenditure	% Spent
FY 2020	5	\$39,816.00	\$29,861.00	75.00%
FY 2021	5	\$39,816.00	\$36,498.00	91.67%
FY 2022	6	\$39,816.00	\$36,498.00	91.67%
FY 2023	10	\$39,816.00	\$36,498.00	91.67%
FY 2024	7	\$39,816.00	\$39,816.00	100.00%
FY 2025	4	\$39,816.00	\$39,816.00	100.00%



Notes:

The number of clients served has dropped to FY 2023 levels.

SUPPORT SERVICE: OUTREACH SERVICES

Service Program

Limitations: NA



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	130	1.6%	\$148,155	\$1,140
FY 2021	8,420	116	1.4%	\$140,761	\$1,213
FY 2022	8,590	155	1.8%	\$151,423	\$977
FY 2023	9,060	240	2.6%	\$153,681	\$640
FY 2024	9,316	282	3.0%	\$163,019	\$578
FY 2025	9,194	236	2.6%	\$161,871	\$686

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost per client
1	Part C	\$80,462	4,248	\$19
2	Part D	\$58,883	5	\$11,777

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost per client
1	Other	\$404,000	50	\$8,080
2	Part C	\$65,491	2,346	\$28
3	Part D	\$125,132	116	\$1,079

CORE SERVICE: SUBSTANCE ABUSE OUTPATIENT

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	0.130%
FY 2021	\$19,018,258.46	0.010%
FY 2022	\$22,372,383.35	0.000%
FY 2023	\$23,801,341.37	0.000%
FY 2024	\$23,557,202.81	0.007%
FY 2025	\$23,594,690.18	0.003%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	\$52,186.00	\$23,556.19	45.14%
FY 2021	\$52,186.00	\$1,356.00	2.60%
FY 2022	\$53,526.00	\$4,971.00	9.29%
FY 2023	\$14,686.00	\$1,440.00	9.81%
FY 2024	\$17,499.00	\$1,560.00	8.91%
FY 2025	\$11,058.00	\$780.00	7.05%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	7	\$44,128.00	\$19,527.19	44.25%
FY 2021	7	\$44,128.00	\$1,146.00	2.60%
FY 2022	9	\$45,468.00	\$4,401.00	9.68%
FY 2023	12	\$6,628.00	\$1,410.00	21.27%
FY 2024	9	\$9,441.00	\$1,440.00	15.25%
FY 2025	8	\$3,000.00	\$780.00	26.00%

Fiscal Year	MAI Ranking	MAI Final Allocation	MAI Final Expenditure	% Spent
FY 2020	4	\$8,058.00	\$4,029.00	50.00%
FY 2021	4	\$8,058.00	\$210.00	2.61%
FY 2022	4	\$8,058.00	\$570.00	7.07%
FY 2023	8	\$8,058.00	\$30.00	0.37%
FY 2024	6	\$8,058.00	\$120.00	1.49%
FY 2025	5	\$8,058.00	\$0.00	0.00%



Notes:

Expenditures have been steadily declining with lowest client and expenditure levels in FY 2025.

CORE SERVICE: SUBSTANCE ABUSE OUTPATIENT

Service Program

Limitations: 400% FPL



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	N/A	0.00%	\$23,556	N/A
FY 2021	8,420	17	0.20%	\$1,356	\$80
FY 2022	8,590	22	0.26%	\$4,971	\$226
FY 2023	9,060	10	0.11%	\$1,440	\$144
FY 2024	9,316	9	0.10%	\$1,560	\$173
FY 2025	9,194	4	0.04%	\$780	\$195

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$11,880	3	\$3,960
2	Other	N/A	7	N/A
3	Part C	\$873	2	\$437

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$47,066	7	\$6,724
2	Other	N/A	8	N/A

SUPPORT SERVICE: SUBSTANCE ABUSE RESIDENTIAL

Ranking, Allocation, and Direct Services Expenditure History

Fiscal Year	Final Expenditure	Category Expense as %
FY 2020	\$17,660,128.37	7.48%
FY 2021	\$19,018,258.46	5.09%
FY 2022	\$22,372,383.35	4.71%
FY 2023	\$23,801,341.37	0.00%
FY 2024	\$23,557,202.81	6.96%
FY 2025	\$23,594,690.18	6.45%

Fiscal Year	Final Allocation	Final Expenditure	% Spent
FY 2020	\$1,773,744.00	\$1,320,120.00	74.43%
FY 2021	\$1,289,469.00	\$968,310.00	75.09%
FY 2022	\$1,538,406.00	\$1,053,590.00	68.49%
FY 2023	\$1,568,552.00	\$1,358,250.00	86.59%
FY 2024	\$1,731,750.00	\$1,639,750.00	94.69%
FY 2025	\$1,611,000.00	\$1,522,000.00	94.48%

Fiscal Year	Part A Ranking	Part A Final Allocation	Part A Final Expenditure	% Spent
FY 2020	9	\$1,773,744.00	\$1,320,120.00	74.43%
FY 2021	8	\$1,289,469.00	\$968,310.00	75.09%
FY 2022	7	\$1,538,406.00	\$1,053,590.00	68.49%
FY 2023	10	\$1,568,552.00	\$1,358,250.00	86.59%
FY 2024	7	\$1,731,750.00	\$1,639,750.00	94.69%
FY 2025	11	\$1,611,000.00	\$1,522,000.00	94.48%



Notes:

FY 2025 client utilization and expenditures are similar to FY 2024 levels.

SUPPORT SERVICE: SUBSTANCE ABUSE RESIDENTIAL

Service Program

Limitations: 400% FPL: 180 day within 12-month period max.



Fiscal Year	RW Clients	Clients Served	Served as % RW Clients	Expenditure	Avg Per Client
FY 2020	8,127	70	0.86%	\$1,320,120	\$18,859
FY 2021	8,420	66	0.78%	\$968,310	\$14,671
FY 2022	8,590	72	0.84%	\$1,053,590	\$14,633
FY 2023	9,060	74	0.82%	\$1,358,250	\$18,355
FY 2024	9,316	88	0.94%	\$1,639,750	\$18,634
FY 2025	9,194	87	0.95%	\$1,522,000	\$17,494

Other Funding Streams 2025

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$233,293	13	\$17,946

Other Funding Streams 2026

	Funder	Expended	Number of Clients	Cost Per Client
1	General Revenue	\$316,876	15	\$21,125

How Dashboard Cards Will Help You Make Data-Based Decisions

Dashboard Card data should be used to determine allocation of funds, assess if other funding streams are emerging to pay for the service, and to estimate needs.



With Dashboard Cards, you can easily see how trends in service utilization are developing for specific services, and you can confidently estimate service-specific expenditures.



Examples:

If **100** clients are expected to access the AIDS Pharmaceutical service category in FY 2027, at a yearly cost of **\$40 per client**, the service category estimated allocation would need to be **\$4,000**.

If the estimated yearly cost per client is \$3,000 for FY 2025, and we serve an estimated **9,100 clients in 2025**, the program needed **\$27.3 million**. Therefore, if we instead serve **9,900 clients in 2027**, the program would require **\$29.7 million**.

When to Use Dashboard Cards



During Needs Assessment:

Priority Setting - Consider prior year's priorities and what other sources fund similar services.

Resource Allocation - Use calculations (like those on the previous slide) to make data-driven decisions on projected resource needs.

Directives - To inform specific directives for the Recipient.



Throughout the Year:

Refer to the data during reallocations(Sweeps) throughout the year.

*Thank
You*



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|---------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



RESCHEDULED!

Miami-Dade HIV/AIDS Partnership New Member Orientation

Originally scheduled:
Wednesday, July 1, 2026

is rescheduled to:

≡ **Wednesday, July 22, 2026** ≡

1:00 p.m. – 4:00 p.m.
via Teams

Registration Required

New Member Orientation is a great opportunity to learn about the Miami-Dade HIV/AIDS Partnership and to gain an understanding of the expectations and responsibilities of Ryan White Program Planning Council members!



All Partnership and Committee members are required to complete New Member Orientation within three months of your membership start date.

To register, please scan the QR Code
or click: https://bit.ly/July_1_2026_NMO



≡ Thank you! ≡

YOUR FEEDBACK MAKES A DIFFERENCE!



Please complete
the evaluation for
TODAY'S MEETING.



Your feedback helps
us improve and plan
for the future.

Thank you!



TOGETHER, WE CAN
make it better!



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|--------------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Care and Treatment
Thursday, July 9, 2026

10:00 a.m. – 1:00 p.m.

Care Resource Community Health Center, Midtown Miami
3510 Biscayne Blvd, 1st Floor, Community Room
Miami, FL 33137

AGENDA

- | | | |
|-------|---|----------------------------|
| I. | Call to Order | Dr. Steven Santiago |
| II. | Introductions | All |
| III. | Meeting Housekeeping | Dr. Steven Santiago |
| IV. | Floor Open to the Public | Dr. Diego Shmuels |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of June 11, 2026 | All |
| VII. | Reports | |
| | • Recipients (Part A and ADAP) | All |
| | • Vacancies | Marlen Meizoso |
| | • Partnership Report (reference only) | Dr. Steven Santiago |
| VIII. | Standing Business | |
| | • FY 2026-27 Rapid Reallocation/Sweeps | All |
| IX. | New Business | |
| | • Miami-Dade County Ryan White Program Demographics FY 2025 | Frank Gattorno |
| | • Miami-Dade County Ryan White Program
FY 2025 Co-Occurring Conditions | Dr. Robert Ladner |
| | • Other Funding and Dashboard Cards | Marlen Meizoso |
| X. | Announcements and Open Discussion | All |
| | • July 22, 2026 New Member Orientation | |
| XI. | Next Meeting: August 13, 2026 at Care Resource | Dr. Diego Shmuels |
| XII. | Adjournment | Dr. Steven Santiago |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Care and Treatment Committee please contact
Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/